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Retention of bile acids (BAs) in the liver during cholestasis plays an important 
role in the development of cholestatic liver injury. Several studies have reported that 
high concentrations of certain BAs induce cell death and inflammatory response in the 
liver, and BAs may promote liver tumorigenesis. Macroautophagy (hereafter referred to 
as autophagy) is a lysosomal degradation process that regulates organelle and protein 
homeostasis and serves as a cell survival mechanism under a variety of stress 
conditions. However, it is not known if BAs modulate autophagy in hepatocytes. In the 
present study, we determined autophagic flux in livers of farnesoid X receptor (FXR) 
knockout (KO) mice that have increased concentrations of hepatic BAs and in primary 
cultured mouse hepatocytes that were treated with BAs. The results showed that 
autophagic flux was impaired in livers of FXR KO mice and in BA-treated primary 
mouse hepatocytes. Mechanistically, BAs did not affect the activities of cathepsin or the 
proteasome, but impaired autophagosomal-lysosomal fusion likely due to reduction of 
Rab7 protein expression and targeting to autophagosomes. In conclusion, BAs 
suppress autophagic flux in hepatocytes by impairing autophagosomal-lysosomal 
fusion, which may be implicated in bile acid-induced liver tumor promotion observed in 
FXR KO mice. 
Alcoholic liver disease encompasses a wide spectrum of pathogenesis including 
steatosis, fibrosis, cirrhosis, and alcoholic steatohepatitis. Acute alcohol treatment 
induces autophagy via FoxO3a-mediated autophagy related gene expression and 
protects against alcohol-induced steatosis and liver injury in mice. Moreover, inhibition 
of autophagy by pharmacological approach or deletion of autophagy genes exacerbates 
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alcohol-induced steatosis and hepatotoxicity. Because we found that FXR KO mice had 
impaired hepatic autophagy and the role of FXR in ethanol hepatotoxicity is not known, 
we thus determined the hepatotoxicity and its mechanisms induced by acute ethanol 
treatment in FXR KO mice. In the present study, wild type and FXR KO mice were 
treated with acute ethanol for 16 hours. We found that ethanol treated-FXR KO mice 
had exacerbated hepatotoxicity and steatosis compared to wild type mice. Furthermore, 
we found that ethanol treatment had decreased expression of various essential 
autophagy genes and several other FoxO3a target genes in FXR KO mice compared 
with wild type mice. Mechanistically, we did not find a direct interaction between FXR 
and FoxO3a. Ethanol-treated FXR KO mice had increased Akt activation, increased 
phosphorylation of FoxO3a resulting in decreased FoxO3a nuclear retention and DNA 
binding. Furthermore, ethanol treatment induced hepatic mitochondrial spheroid 
formation in FXR KO mice, but not in wild type mice, which may serve as a 
compensatory alternative pathway to remove ethanol-induced damaged mitochondria in 
FXR KO mice. Moreover, induction of FXR with WAY-362450 protected against acute 
ethanol-induced steatosis, but not hepatotoxicity. These results suggest that lack of 
FXR impaired FoxO3a-mediated autophagy and in turn exacerbated alcohol-induced 
liver injury.  
In conclusion, this dissertation provided novel insights in how two different liver 
pathologies may cross talk. We demonstrated that the increased hepatic bile acid levels 
lead to impaired autophagy through the inhibition of autophagosomal-lysosomal fusion. 
Moreover, FXR deficiency exacerbated alcohol induced hepatotoxicity and steatosis 
likely by two mechanisms: bile acid-mediated inhibition of autophagy and Akt-mediated 
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repression of ethanol-induced FoxO3a activation. This dissertation presented novel 
therapeutic targets for both cholestasic liver injury and alcoholic liver disease. 
Autophagy and FXR are possible therapeutic targets for cholestasis, whereas, FXR and 
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1.1 Physiological and pathological roles of bile acids 
Bile acids are amphipathic detergent-like molecules synthesized as end products 
of cholesterol catabolism in hepatocytes through multiple enzymatic steps, and are 
classified as either primary bile acids, synthesized in the liver, or secondary bile acids, 
synthesized in the intestines (Modica, Gadaleta et al. 2010). The majority of the 
circulating bile acids are glycine or taurine conjugated. Bile acids are planar 
amphipathic molecules with hydrophilic alpha face containing hydroxyl groups and 
hydrophobic beta face containing no substituents, and the modifications and conjugates 
on the carbon backbone determine the hydrophobicity and subsequent toxicity (Figure 
1.1) (Modica, Gadaleta et al. 2010). Moreover, the hydrophobicity index of bile acids is 
determined using high pressure liquid chromatography (HPLC), but it should be 
cautioned that the HPLC method is imperfect (Hofmann and Hagey 2008). Nevertheless 
it is generally accepted that ursodeoxycholic acid (UDCA) is one of the most hydrophilic 
bile acids and deoxycholic acid (DCA) is one of the most hydrophobic bile acids 
(Modica, Gadaleta et al. 2010).  
Furthermore, the well-known physiological functions of bile acids include hepatic 
bile formation and absorption of dietary lipids and fat-soluble vitamins (Lefebvre, Cariou 
et al. 2009).  Moreover, bile acids participate in various physiological processes 
including regulation of their own homeostasis, adaptive responses to cholestasis and 
other insults to the liver, lipid metabolism, and glucose metabolism (Monte, Marin et al. 
2009). Bile acids are synthesized in the liver, stored in the gallbladder, and secreted into 
the small intestines to facilitate the absorption of lipids and vitamins. When the flow of 
bile acids from the liver to the duodenum is obstructed, resulting in accumulation of bile 
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acids in the liver, this condition is know as cholestasis.  Recent research and 
discoveries show that bile acids are not passive players, but are involved with multiple 
physiological functions, especially glucose and lipid metabolism inside and outside of 






















Bile Acid Structure 
Bile acids are synthesized from cholesterol backbone, and hydroxylation of bile acids 
alters hydrophobicity. UDCA is a hydrophilic primary bear bile acid. CA and CDCA 
are primary human bile acids. DCA is a hydrophobic secondary bile acid. Bile acids 
are conjugated prior to transport out of the hepatocytes into the bile canaliculi. Figure 
is reprinted with permission from Deciphering the Nuclear Bile Acid Receptor FXR 
Paradigm, Volume 8, Modica S, Gadaleta RM, and Moschetta A, Nuclear Receptor 
Signaling, e005, Copyright (2010), with permission from the publisher.  
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1.2 Bile acids synthesis and enterohepatic circulation 
Primary bile acids are the result of a multistep cholesterol catabolism performed 
by various enzymes including several cytochrome P450s (CYPs). In the classic 
pathway, cholesterol is first converted into 7-α-hydroxycholesterol by CYP7A1 in the 
endoplasmic reticulum (ER). 7-α-hydroxycholesterol is then primarily converted to cholic 
acid (CA) in multistep enzymatic reactions involving CYP8B1 and CYP27A1 (Chiang 
1998; Lefebvre, Cariou et al. 2009). In the alternative or acidic pathway when the 
CYP7A1 level is low, CYP27A1 in the mitochondria converts cholesterol into 27-
hydroxycholesterol. Multistep enzymatic reactions involving CYP7B1 modify 27-
hydroxycholesterol into chenodeoxycholic acid (CDCA). It has been suggested that 
classic pathway is the pathway under normal physiological conditions whereas the 
alternate pathway becomes the major pathway to compensate for low bile acids 
synthesis in certain liver diseases.  CA and CDCA then undergo taurine or glycine 
conjugation mediated by bile acid CoA amino acid N-acyltransferase (BAAT) and bile 
acid CoA synthase (BACS) respectively to increase water solubility.  
Conjugated bile acids are transported into the bile canaliculi and subsequent bile 
ducts via the ATP binding cassette transporter ABCB11, also commonly known as bile 
salt exporting pump (Bsep) (Gerloff, Stieger et al. 1998). Once in the bile ducts, bile 
acids travel toward the small intestines and are secreted to assist in absorption of fatty 
acids and water insoluble vitamins. The bile acids are reabsorbed from the ileum by the 
apical sodium-dependent bile acid transporter (ABST) (Wong, Oelkers et al. 1995). Bile 
acid receptor, Farnesoid X Receptor (FXR), is then activated in the enterocytes by bile 
acids and induces fibroblast growth factor 15/19 (FGF15/19) secretion, a hormone 
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responsible for negative regulation of bile acids synthesis (Schaap, van der Gaag et al. 
2009; Gadaleta, van Mil et al. 2010). Organic solute transporters (Ost) that exist in its 
heterodimeric form containing Ostα and Ostβ transport the bile acids into the portal vein 
to return them to the liver for recycling (Dawson, Hubbert et al. 2005; Gadaleta, van Mil 
et al. 2010). Sodium-taurocholate cotransporter protein (NTCP), and organic anion 
transporting polypeptide (OATP) absorb the bile acids back into the hepatocytes. This 
cycle is known as enterohepatic circulation, which is responsible for the tight regulation 
































Bile acids are synthesized from cholesterol through multienzymatic synthesis 
involving CYPs and are glyco- or tauro-conjugated by BAAT or BACS. Conjugated 
bile acids are transported into bile canaliculi by Bsep, and are secreted into the small 
intestines. ABST transports bile acids into enterocytes in the ileum, and FXR is 
activated by bile acids to induce FGF15/19 production and secretion. Bile acids then 
are transported into portal vein by Ostα/β and returned to the liver. OATPs and NTCP 
facilitate the absorption of bile acids into the liver.  
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1.3 Impaired flow of bile acids results in liver injury  
Disruption in the enterohepatic circulation, either inside or outside of the liver 
results in cholestasis, one of the frequent indicators for liver transplantation (Murray and 
Carithers 2005). Currently, UDCA, a hydrophilic bile acid, is the only drug approved to 
treat cholestasis (Paumgartner 2006). Intrahepatic cholestasis occurs when the bile flow 
is disrupted inside the liver, and extrahepatic cholestasis occurs when disruption of the 
bile flow occurs outside of the liver. Known etiologies of cholestasis include gallstones, 
biliary trauma, cystic fibrosis, primary biliary cirrhosis, primary sclerosing cholangitis, 
tumors, and drugs (e.g. erythromycin and flucloxacillin) (Hirschfield, Heathcote et al. 
2010; Padda, Sanchez et al. 2011). Manifestations of cholestasis include hepatic bile 
acids accumulation, hepatic inflammation, fibrosis and inevitably, cirrhosis (Gadaleta, 
van Mil et al. 2010). Excessive amount of bile acids is clearly cytotoxic.  
At higher concentrations, bile acids exert cytotoxicity due to their detergent-like 
properties (Lefebvre, Cariou et al. 2009), and cholestasis is accompanied by liver injury 
including destruction of bile ducts and hepatocyte death. Plasma membrane damage, 
oxidative stress, mitochondrial dysfunction, apoptosis, and inflammation all are cell 
injury mechanisms exerted by the cytotoxic nature of bile acids (Perez and Briz 2009; 
Allen, Jaeschke et al. 2011). Moreover, the cytotoxicity induced by bile acids relies on 
their hydrophobicity. Hydrophobic bile acids including chenodeoxycholic acid have the 
ability to enter the lipid membrane and disrupt the structure and function of the 
membrane and cells leading to the inevitable apoptosis (Billington, Evans et al. 1980; 
Perez and Briz 2009). However, the mechanism of bile acid-mediated cell death in 
cholestatic liver disease and whether it is mediated by apoptosis or necrosis is a 
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controversial issue (Woolbright and Jaeschke 2012). Obstructive cholestasis in bile 
duct-ligated mice demonstrated increased focal necrosis, increased plasma necrosis 
biomarkers and a lack of apoptosis plasma biomarkers (Woolbright, Antoine et al. 
2013). Nevertheless, it is well established that direct bile acid toxicity in vitro result in 
apoptosis. However, the mechanism of bile acid toxicity in vivo needs to be further 
studied.  
Interestingly, hydrophilic bile acids, in particular UDCA, have been shown to be 
cytoprotective. Indeed, UDCA is used as therapeutic agent for cholestasis and has been 
suggested to exert three major protective mechanisms including protecting 
cholangiocytes against hydrophobic bile acids, stimulating hepatobiliary secretion and 
protecting hepatocytes from bile acids induced apoptosis (Paumgartner and Beuers 
2002).   
1.4 Farnesoid X Receptor is the master regulator of bile acid homeostasis 
FXR, a former orphan nuclear receptor, is the master regulator of bile acid 
homeostasis, and bile acids, in particular, CDCA, are the endogenous ligands for FXR 
(Forman, Goode et al. 1995; Seol, Choi et al. 1995; Makishima, Okamoto et al. 1999; 
Parks, Blanchard et al. 1999; Wang, Chen et al. 1999). Synthetic ligands such as 
GW4064 also can activate FXR (Maloney, Parks et al. 2000). The n-terminus of FXR 
contains a ligand-independent transcriptional activation function (AF-1), a DNA-binding 
domain consisting of two highly conserved zinc finger motifs, and a hinge region that 
allows simultaneous receptor dimerization and DNA binding (Chawla, Repa et al. 2001). 
The c-terminus contains a ligand binding domain, a dimerization interface and a ligand-
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dependent activation function (AF-2) (Figure 1.3) (Chawla, Repa et al. 2001).  FXR 
binds to an inverted repeat-1 (IR-1) response element, an inverted AGGTCA sequence 
separated by one base pair, as either a monomer or a heterodimer with Retinoid X 
Receptor α (RXRα) (Lefebvre, Cariou et al. 2009). Furthermore, ligand binding induces 
FXR-RXR heterodimer to dissociate from co-repressors and recruit co-activators to 
initiate target gene transcription (Modica, Gadaleta et al. 2010). Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) is one known co-activator of 
FXR and is shown to induce FXR activation in a ligand dependent manner by interacting 
with FXR-RXR heterodimer (Kanaya, Shiraki et al. 2004; Savkur, Thomas et al. 2005; 
Kanaya and Jingami 2006). Moreover FXR can be regulated by post-translational 
modifications. Acetylation of FXR by p300 stabilizes the molecule but inactivates FXR 
interaction with RXR and DNA binding. FXR acetylation can be reversed by sirtuin-1 
(Sirt1), a NAD-dependent deacetylase (Kemper, Xiao et al. 2009). FXR is highly 
expressed in the liver and intestines and regulates the enterohepatic circulation of the 


























Structure of Farnesoid X Receptor.  
FXR contains five regions: a ligand-independent activation factor (AF1), a DNA-
binding domain, a hinge domain, a ligand-binding domain, and a ligand-dependent 
activation factor (AF2). 
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FXR is involved with bile acids homeostasis essentially through transcriptional 
regulation of genes involved with bile acids synthesis and transport. In the liver, FXR 
regulates bile acid levels by activating small heterodimer partner (SHP), a co-repressor, 
which then interacts with liver receptor homolog-1 (LRH-1) to inhibit gene transcription 
of bile acid synthesis enzymes, CYP7A1 and CYP8B1. The decrease in bile acid 
synthesis enzymes subsequently down regulates bile acid synthesis (Goodwin, Jones et 
al. 2000; Lee, Lee et al. 2006; Sanyal, Bavner et al. 2007). FXR also regulates bile 
acids synthesis through a second mechanism in the intestines. Activation of FXR by bile 
acids induces FGF15/19 secretion from the intestines (Inagaki, Choi et al. 2005). 
Activated and released FGF15/19 then travels from the intestines to the liver by portal 
circulation and binds to fibroblast growth factor receptor 4 (Fgfr4) in liver to suppress the 
transcription of Cyp7a1 and subsequent inhibition of bile acid synthesis (Lefebvre, 
Cariou et al. 2009). Indeed, FGF15/19 is the key regulator of bile acid synthesis through 
intestinal FXR activation (Kong, Wang et al. 2012). Whole body FXR knockout (KO) 
mice displayed elevated bile acids due to increased synthesis (Sinal, Tohkin et al. 2000; 
Kim, Ahn et al. 2007), whereas hepatocyte specific FXR KO mice displayed normal 
levels of bile acids (Kim, Ahn et al. 2007; Borude, Edwards et al. 2012).  
FXR deficiency leads to spontaneous liver tumorigenesis including hepatocellular 
carcinoma (HCC), adenoma and hepatocholangiocellular carcinoma (Kim, Morimura et 
al. 2007; Yang, Huang et al. 2007).  Indeed, FXR and its target gene, SHP, are 
downregulated in human HCC samples (Takahara, Takahashi et al. 2008; Wolfe, 
Thomas et al. 2011; Liu, Meng et al. 2012; Su, Ma et al. 2012). Therefore, FXR is 
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suspected to be a tumor suppressor in the liver. However, it is currently not clear how 
elevated bile acid levels and FXR deficiency leads to liver tumorigenesis.  
1.5 FXR is a modulator of lipid and glucose metabolism 
 FXR has been reported to regulate pathways involved with lipid, glucose and 
energy metabolism. FXR lowers hepatic triglycerides via SHP-mediated inhibition of 
sterol regulatory binding protein 1 (SREBP1)-mediated hepatic lipogenesis (Watanabe, 
Houten et al. 2004). Additionally, FXR decreases plasma triglycerides by increasing 
apolipoprotein CII (apoCII), a co-activator of lipoprotein lipase (Kast, Nguyen et al. 
2001), and inhibiting apoCIII, a co-inhibitor of lipase, thus FXR activation promotes 
lipase-mediated plasma triglyceride clearance (Claudel, Inoue et al. 2003).  
 FXR also plays a role in glucose metabolism by cross-talking with insulin. Insulin 
has been shown to regulate FXR, however, FXR is also involved in improving insulin 
sensitivity. FXR deficient mice exhibited decreased insulin sensitivity and impaired 
glucose tolerance (Cariou, van Harmelen et al. 2006; Ma, Saha et al. 2006; Zhang, Lee 
et al. 2006), whereas, pharmacological activation or constitutive activation of FXR 
improved insulin sensitivity and glucose tolerance. The mechanism of how FXR 
improves insulin sensitivity and glucose tolerance is not completely understood because 
the expression of FXR is non-existent in skeletal muscles, and very low in adipose 
tissues. However, a phenomenon known as lipotoxicity may explain how FXR is 
involved with regulation of insulin sensitivity and glucose levels (Modica, Gadaleta et al. 
2010). Activation of FXR reduces lipotoxicity by reducing circulating triglycerides and 




















FXR Improves Insulin Sensitivity and Glucose Tolerance.  
Insulin promotes FXR activation. Activated FXR then increases expression of ApoCII, 
a co-activator of lipoprotein lipase, and decreases ApoCIII, an inhibitor of the lipase. 
Increased lipase activity clears plasma triglycerides and decreases lipotoxicity. 
Decreased lipotoxicity coupled with FXR activation improves insulin sensitivity and 




1.6 Autophagy  
 Macroautophagy, hereafter called autophagy, is a cellular protective mechanism 
responsible for disposing and recycling damaged organelles and proteins, and thus 
promotes cell survival. The autophagy process is characterized by development of the 
isolation membrane into the autophagosome; in which, the autophagosome will fuse 
with the lysosome to degrade the engulfed substances. Currently there are more than 
30 Atg genes identified to be involved with autophagy or autophagy like processes in 
yeast, and most of them have mammalian homolog counterparts (Klionsky and Emr 
2000). Moreover, there is accumulating evidence revealing that autophagy is a tumor 
suppressing process.  
1.7 Multiple signaling pathways regulate autophagy 
Autophagy is usually induced under stress conditions including intracellular 
pathogens, hypoxia, increase in reactive oxygen species, endoplasmic reticulum, 
starvation, amino acids deprivation, radiation, proteasome inhibition and protein 
aggregates (Ding, Manley et al. 2011). Rapamycin, an inhibitor of mammalian target of 
rapamycin (mTOR) complex (mTORC), induces autophagy, which reveals that mTORC 
is a regulator of autophagy (Blommaart, Luiken et al. 1995; Kamada, Sekito et al. 2004). 
mTOR is a serine/threonine kinase complex composed of two heteromeric complexes, 
mTORC1 and mTORC2 (Yang and Guan 2007). In addition to regulation of autophagy, 
mTOR has multiple functions including translation regulation by phosphorylating two 
proteins: 70 kDa ribosomal protein S6 kinase-1 (p70S6K) and translational initiation 
factor 4E binding protein-1 (4EBP1), which activates the protein synthesis (Inoki, Zhu et 
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al. 2003). In addition to translation regulation, mTOR is also responsible for sensing the 
nutrient levels from the upstream signaling pathways.  
Class 1 phosphatidylinosital-3 kinase (PI3K) signaling pathway is the canonical 
signaling pathway that regulates mTOR. When PI3K signaling pathway is activated by 
the growth factors, PI3K phosphorylates Akt, which activates mTOR through the 
phosphorylation of tuberous sclerosis protein 2 (TSC2). TSC2 is part of a complex that 
is also composed of tuberous sclerosis protein 1 (TSC1) and is responsible for negative 
regulation of autophagy (Yang and Guan 2007). In a stable TSC complex, TSC2 
induces GTPase-activating protein (GAP) activity, therefore, accelerating GTP 
hydrolysis of Rheb, a small GTPase, converting Rheb from active GTP bound form to 
inactive GDP bound form. Inactive Rheb subsequently inhibits mTOR and activates the 
autophagic process (Jung, Ro et al. 2010; Yang and Klionsky 2010). Therefore, when 
TSC2 is phosphorylated, the TSC complex is dissociated rendering TSC2 inactive 
resulting in activation of mTOR, and suppression of the autophagic process.  
Moreover, AMP-activated protein kinase (AMPK) signaling pathway also 
regulates mTOR. The role of AMPK signaling pathway in autophagy regulation is still 
controversial. To reflect on energy stress condition, the AMP/ATP ratio increases, and 
the excess AMP binds to and activates AMPK. In turn, AMPK phosphorylates TSC2 and 
increases the TSC2 GAP activity toward Rheb in which inhibits mTOR (Inoki, Zhu et al. 
2003). It has been show that the expression of the dominant negative form of AMPK 
completely inhibits autophagy in hepatocytes, HT-29 and Hela cells (Meley, Bauvy et al. 
2006). However, the adenosine analog, adenosine 5-amino-4-imidazole carboxamide 
riboside (AICAR) activates AMPK and actually suppresses autophagy in hepatocytes 
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(Samari and Seglen 1998). In contrary, compound C inhibits AMPK and induces 
autophagy in cancer cells by down regulating the Akt-mTOR pathway (Vucicevic, 
Misirkic et al. 2011). In conclusion, the role of AMPK in autophagy needs to be clarified 
by studying possible off-target effects of activators and inhibitors of AMPK. In addition to 
the pharmacological approaches, it will be better to study autophagy by genetically up-
regulating or knocking down AMPK. 
mTOR is the primary regulator of autophagy, however, autophagy can be 
activated by mTOR-independent pathways. Agents that reduce the cAMP levels have 
been shown to induce mTOR-independent autophagy including calpain inhibitors and L-
type Ca2+ channel agonists (Ravikumar, Sarkar et al. 2010). In addition to the decrease 
in cAMP levels, drugs that decrease the intracellular inositol and inositol 1,4,5-
triphosphate (IP3) concentrations also induce mTOR-independent autophagy. Examples 
of common drugs that reduce inositol include lithium, carbamazepine and valproic acid 
(Sarkar, Floto et al. 2005; Ravikumar, Sarkar et al. 2010). The general consensus is 
that autophagy is usually induced under stress conditions to act as a cell protective 

























Akt and AMPK signaling pathways regulate mTOR. 
Activation of Akt pathway inhibits TSC complex, activates Rheb, and subsequently 
activates mTOR complex, which inhibits autophagy. AMPK activates TSC complex, 
therefore, inhibits mTOR and induces autophagy. mTOR complex activates protein 




1.8 From isolation membrane to autophagosome 
Induction of autophagy requires several multimolecular complexes including the 
following: ULK1 (UNC-51 like kinase) protein kinase complex, vacuolar protein sorting 
34 (VPS34)-Beclin-1 class III PI3-kinase complex, Atg9-Atg2-Atg18 complex, and Atg5-
Atg12-Atg16 and Atg8/LC3 (microtubule-associated protein 1 light chain 3) conjugation 
systems (Figure 1.6) (Ding, Manley et al. 2011). Generally the ULK1 complex initiates 
the autophagy process and then two ubiquitin-like conjugation systems including Atg7, 
Atg3, and Atg10 and Atg5-Atg12-Atg16 complex promote the conjugation of light chain 
3, a mammalian homolog of Atg8, with phosphatidylethanolamine (PE) to form the PE 
conjugated form of LC3 (LC3-II) (Kabeya, Mizushima et al. 2000; Ohsumi 2001; Chan, 
Longatti et al. 2009; Hosokawa, Hara et al. 2009). LC3-II then translocates to the early 
autophagosomal membrane to initiate membrane elongation and formation of double 
membrane structures (Kabeya, Mizushima et al. 2000). The autophagosome 
subsequently fuses with the lysosome to become a mature autolysosome to complete 
the degradation process (Kimura, Noda et al. 2007; Saftig, Beertsen et al. 2008).  
The ULK complex consists of ULK1 (Atg1 homolog), FIP200 (Atg 17-like 
molecule), Atg13 and Atg101, and is localized in the cytosol (Ganley, Lam du et al. 
2009; Hosokawa, Hara et al. 2009; Mizushima 2010). Upon autophagy induction, the 
complex initiates the formation of the autophagic isolation membrane. Further on, the 
mTOR regulates the activity of the ULK complex through phosphorylation, and the ULK 
complex is activated by dephosphorylation (Ding, Manley et al. 2011). Furthermore, 
ULK is a serine/threonine protein kinase responsible for phosphorylating Atg13 and 
FIP200 and recruiting downstream autophagy proteins for the autophagosome 
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formation (Chan, Longatti et al. 2009). Moreover, ULK complex is involved in cross-
talking with the VPS34-Beclin-1 class III PI3-kinase complex as a regulatory mechanism 
in early autophagy induction (Jung, Ro et al. 2010). 
Beclin-1, an Atg6 homolog, is imperative for initiation and regulation of the 
autophagy process by establishing a complex with VPS34, VPS15, and Atg14 (Itakura, 
Kishi et al. 2008). The Bcl family proteins, Bcl-2 and Bcl-x, which dissociate Beclin-1 
from the VPS34, by binding with Beclin-1, negatively regulate the activity of Beclin-1 
(Pattingre, Tassa et al. 2005; He and Levine 2010). One of the major functions of 
Beclin-1 complex is to promote the activation of VPS34, a class III PI3-kinase 
responsible for producing phosphatidylinositol-3-phosphate (PI-3-P) (Kihara, Kabeya et 
al. 2001; Kihara, Noda et al. 2001; Zeng, Overmeyer et al. 2006; Ding, Manley et al. 
2011). Moreover, Beclin-1 also interacts with other proteins responsible for inducing 
autophagy, including UV radiation resistance-associated gene protein (UVRAG) and 
Ambra-1 (Liang, Feng et al. 2006; Fimia, Stoykova et al. 2007). In addition, Bif-1 
positively regulates the Beclin-1 complex by interacting with UVRAG, and Rubicon 
interacts directly with VPS34 to negatively regulate the Beclin-1 complex (Zhong, Wang 
et al. 2009; Sun, Zhang et al. 2011). 3-methyladenine (3-MA) is a class III PI3-kinase 
inhibitor and acts on VPS34, which inhibits autophagosome formation (Seglen and 
Gordon 1982).  
A bilayered lipid membrane is required for autophagosome formation. Atg9 is a 
transmembrane protein with six transmembrane domains with its carboxyl termini in the 
cytosol and is conserved in all species. Atg9 is responsible for recruiting the lipid 
membrane to a pre-autophagosomal structure known as phagophore assembly site 
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(PAS) (Young, Chan et al. 2006; Webber and Tooze 2010). In mammalian cells, Atg9 
exists as two functional orthologs, Atg9L1 and Atg9L2. Atg9L2 is only expressed in the 
placenta and pituitary gland whereas Atg9L1 is ubiquitously expressed (Yamada, 
Carson et al. 2005). Atg9 interacts with Atg18, a PI-3-P binding protein, and Atg2, a 
peripheral membrane protein, in the PAS (Wang, Kim et al. 2001; Reggiori, Tucker et al. 
2004; Obara, Sekito et al. 2008). The source of the membrane is unknown, but it has 
been proposed that Atg9 is cycled between the trans-Golgi network, late endosomes 
and the PAS to recruit additional membranes for autophagosomes (Young, Chan et al. 
2006; Webber and Tooze 2010). Other possible membrane sources that have been 
proposed for the origin of autophagosomes include the plasma membrane, ER and 
mitochondrial contact site, endosomal membrane, and mitochondrial membrane (Tooze 
and Yoshimori 2010; Lamb, Yoshimori et al. 2013). Finally, the de novo synthesis model 
is feasible since it appears that the phagophore expands rather than being formed in a 
single step from the existing membrane (Chen and Klionsky 2011).  
Finally, two ubiquitin-like conjugation systems play a role as the engine in 
autophagy machinery by regulating the elongation of the isolation membrane that 
engulfs the substances to form the autophagosome (Ohsumi 2001). Without this core 
complex, autophagy cannot occur. In the first system, Atg12, a ubiquitin-like protein, is 
activated by Atg7, a ubiquitin-activating enzyme (E1)-like protein, which enables Atg 10, 
a ubiquitin carrier (E2)-like protein, to transfer Atg12 to establish a covalent bond with 
Atg5 (Mizushima, Noda et al. 1998; Ichimura, Kirisako et al. 2000; Suzuki, Kirisako et al. 
2001). The Atg5-Atg12 complex then interacts with Atg16 to establish ubiquitin ligase 
(E3)-like Atg5-Atg12-Atg16 complex that is required for autophagy activation and 
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localization of LC3 to the autophagosomal membrane (Hanada, Noda et al. 2007). In 
the second ubiquitin-like conjugation system, Atg4 cleaves LC3 to expose the 
conserved Gly120 residue in the c-terminus. PE then is conjugated to the unconjugated 
form of LC3 (LC3-I) at Gly120 via Atg7 and Atg3, an E2-like protein, to form the 
conjugated form of LC3 (LC3-II) (Kabeya, Mizushima et al. 2000; Ohsumi 2001). LC3-I 
is found in cytosol whereas LC3-II is localized on the autophagosomal membrane. LC3-
II is required for completion of elongation and closure of the membrane into a mature 
autophagosome (Kabeya, Mizushima et al. 2000; Kirisako, Ichimura et al. 2000). Unlike 
other Atg proteins such as Atg5, Atg7 or Atg16 that are found only transiently 
associated with autophagosomal membrane, LC3-II is relatively stable on the 
autophagosomal membrane (Rubinsztein, Cuervo et al. 2009; Mizushima, Yoshimori et 
al. 2010; Klionsky, Abdalla et al. 2012). Therefore, LC3 is commonly used as a marker 


























Autophagy machinery.  
Autophagy involves the formation of double-membrane autophagosomes that fuse 
with lysosomes to form autolysosomes for the degradation of intracellular proteins 
and organelles. At least four important functional groups of Atg proteins are required 
for autophagy: (1) ULK1 protein- kinase complex and (2) VPS34 – Beclin 1 class III 
PI3-kinase complex regulate autophagy initiation; (3) Atg9 – Atg2 – Atg18 complex 
regulates expansion of phagophore assembly site (PAS) by carrying lipids; and (4) 
the Atg5 – Atg12 – Atg16 and LC3 conjugation systems regulate the elongation of 
autophagosome membranes. Phosphatidylethanolamine (PE)-conjugated LC3 
(called LC3-II) remains on the isolation membranes and autophagosome 
membranes, whereas the Atg12 – Atg5 – Atg16 complex transiently associates with 
the isolation membranes and dissociates from the autophagosome membranes. 
Once autophagosomes fuse with lysosomes to form autolysosomes, the inner 
membrane LC3-II is degraded by lysosomal enzymes whereas the outer membrane 
LC3-II is de-conjugated and recycled. Pharmacological autophagy inhibitors such as 
3-methyladenine (3-MA) and chloroquine (CQ) are also highlighted. 
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1.9 Autophagosomal-lysosomal fusion is required for completion of autophagy 
degradation process 
Degradation of engulfed substance in the autophagosome is dependent on the 
autophagosomal-lysosomal fusion and also the lysosomal functions. It has been shown 
that microtubule dependent lysosomal positioning is critical for regulation of the 
autophagosomal-lysosomal fusion process (Korolchuk, Saiki et al. 2011). Newly formed 
autophagosomes are randomly scattered across the cytoplasm; however, during 
maturation, the autophagosomes use microtubules to move toward the microtubule 
organizing center where the lysosomes are present (Yamamoto, Tagawa et al. 1998). 
At the microtubule organizing center, an autophagosome fuses with a lysosome via 
interaction of assorted fusion proteins found on both the autophagosome and the 
lysosome. Chemicals such as vinblastine and nocodazole that disrupt the microtubule 
stability and structure thus can inhibit autophagy by impairing the fusion process 
(Kovacs, Reith et al. 1982; Webb, Ravikumar et al. 2004).  
Furthermore, multiple proteins including lysosomal associated membrane 
proteins 1 and 2 (LAMP-1, LAMP-2), Rab proteins and soluble n-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs) mediate the fusion of 
autophagosomes to lysosomes (Jager, Bucci et al. 2004; Kimura, Noda et al. 2007; 
Saftig, Beertsen et al. 2008). LAMP-1 and LAMP-2 are well known lysosomal 
membrane markers, and LAMP-2 depletion decreases fusion (Gonzalez-Polo, Boya et 
al. 2005). This suggests that LAMP-1 and LAMP-2 are responsible for coordinating the 
fusion of the lysosome with the autophagosome, however the precise mechanism is not 
yet fully understood. Rab proteins are members of small GTP-binding proteins and are 
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responsible for binding to the membranes as well as recruiting effectors of fusion. Rab7 
is a required component for a complete autophagosomal-lysosomal fusion (Ganley, 
Wong et al. 2011). Along with Rab7, post-Golgi SNAREs including vesicle-associated 
membrane protein 7 (VAMP7), vesicle t-SNARE-interacting protein homologous 1B 
(Vti1b) and syntaxin-7 also are required for the autophagosomal-lysosomal fusion 
(Pryor, Mullock et al. 2004; Fraldi, Annunziata et al. 2010; Furuta, Fujita et al. 2010). 
When autophagosomal-lysosomal fusion is completed, the newly formed autolysosome 
degrades the substrate through the enzymatic activity inside the autolysosome.  
1.10 Cathepsins, hydrolases and lysosomal pH drive lysosomal degradation 
process 
The completion of the autophagy process is dependent on the lysosomal 
degradation process. Lysosomes were first identified and described by Christian de 
Duve in 1955 as a cytosolic membrane structure containing at least 50 acid hydrolases 
that are pH sensitive including phosphatases, nucleases, glycosidases, proteases, 
peptidases, sulphatases and lipases (de Duve 1983). Due to the wide range of enzymes 
contained in lysosomes, lysosomes are capable of degrading all macromolecules found 
in the cell in order to recycle.  
Cathepsins are the best-studied lysosomal hydrolases and can be divided into 
three subgroups according to their active amino acid sites including cysteine, aspartate 
and serine (Rawlings, Tolle et al. 2004). Additionally, cathepsins are proteases with pKa 
values of approximately 3.5 and 8.0, which are imperative for its enzymatic function 
(Turk and Turk 2009). Aspartic protease cathepsin D is the most common lysosomal 
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protease along with various cysteine cathepsins including cathepsins B and C (Turk, 
Stoka et al. 2002). The cathepsins do not have high substrate specificity, which 
contributes to their ability to degrade a wide range of proteins (Turk and Turk 2009). 
The enzymatic activity of cathepsins relies on the relatively low pH level (3.8-5) well 
characterized in the lysosome.  Nevertheless, most of the cathepsins still can function at 
neutral pH with either decreased stability or altered specificity (Turk, Turk et al. 2001).  
Further on, lysosomal degradation is attributed to the cooperative efforts between 
pH sensitive enzymes and proteins responsible for pH maintenance.  Proton pumping 
vacuolar ATPases, chloride transporters and cAMP-regulated chloride channels 
regulate the pH level in the lysosomes (Kornak, Kasper et al. 2001; Forgac 2007; 
Graves, Curran et al. 2008; DiCiccio and Steinberg 2011). Furthermore, when the 
lysosome pH is raised, the lysosome function is impaired by inactivation of lysosomal 
pH sensitive enzymes including the acid hydrolases and cathepsins. Interestingly, when 
the lysosomal membrane permeabilization event occurs, the contents and cathepsins 
are released from the lysosome and trigger apoptosis. In addition, the rapid rupture of 
lysosomes may result in necrosis (Kroemer and Jaattela 2005).  
1.11 Autophagy is required for cell survival and suppresses tumorigenesis 
Autophagy is a cellular protective mechanism and the suppression of autophagy 
has serious consequences. Beclin-1 knockout mice die in utero whereas Atg3, Atg5, 
Atg7, Atg9, and Atg16L knockout mice die within a day after birth (Qu, Yu et al. 2003; 
Yue, Jin et al. 2003; Kuma, Hatano et al. 2004; Komatsu, Waguri et al. 2005; Saitoh, 
Fujita et al. 2008; Sou, Waguri et al. 2008; Saitoh, Fujita et al. 2009; Mizushima and 
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Levine 2010). Moreover, FIP200 and Ambra1 deletions are also embryonic lethal in 
mice (Gan, Peng et al. 2006; Fimia, Stoykova et al. 2007). Therefore, autophagy is 
required for viability, especially during the embryonic development.   
Because of the autophagy gene knockout mice are either embryonic lethal or die 
at neonatal stage, tissue specific genetic knockout mice have been developed. Liver-
specific Atg5 or Atg7 knockout mice develop liver injury, hepatomegaly, inflammation, 
fibrosis and spontaneous liver tumors (Mizushima and Levine 2010; Inami, Waguri et al. 
2011; Takamura, Komatsu et al. 2011; Ni, Boggess et al. 2012). Furthermore, Beclin-1 
heterozygous mice are more susceptible to liver tumorigenesis (Qu, Yu et al. 2003). 
Suppression of autophagy also results in the accumulation of ubiquitinated protein 
aggregates and damaged organelles, including mitochondria, leading to cellular 
dysfunction (Komatsu, Waguri et al. 2005; Hara, Nakamura et al. 2006; Komatsu, 
Waguri et al. 2006; Kim, Rodriguez-Enriquez et al. 2007; Mizushima 2007; Nakai, 
Yamaguchi et al. 2007; Raben, Hill et al. 2008). Mechanistically, it appears that the 
persistent activation of Nrf2 due to the accumulation of p62 in autophagy-deficient liver 
is responsible for the pathogenesis observed in autophagy-deficient livers. The 
mechanisms by which p62 activates Nrf2 is discussed below. Further deletion of p62 
reduced hepatomegaly, liver injury and the number of tumors in liver-specific Atg7 
knockout mice (Takamura, Komatsu et al. 2011).  We recently also reported that further 
deletion of Nrf2 completely rescued hepatomegaly, liver injury and liver tumors in liver-
specific Atg5 knockout mice (Ni, Woolbright et al. 2014). Why persistent Nrf2 activation 
would trigger liver injury in liver-specific Atg5 knockout mice is currently still not clear. 
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1.12 p62 is an autophagy substrate with multiple roles 
p62 is a scaffold protein with multiple domains known for signaling transduction 
modulations and also plays a role in mediating the balance between the cell survival 
and death (Figure 1.7) (Moscat and Diaz-Meco 2009). The PB1 domain in the n-
terminus is responsible for interacting with atypical protein kinase C (aPKC) and polarity 
protein, Par-6, which implicate the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) function downstream (Sanz, Diaz-Meco et al. 2000; Duran, 
Serrano et al. 2004; Moscat and Diaz-Meco 2009). In addition, the PB1 domain is 
suspected to play a role in p62 oligmerization that allows p62 to establish a signal 
organizing center in order to interact with other signaling molecules (Moscat, Diaz-Meco 
et al. 2006; Moscat, Diaz-Meco et al. 2007). Located next to the PB1 domain is the ZZ 
zinc finger region responsible for binding to receptor interacting protein (RIP), a TNFα 
signaling adaptor (Sanz, Sanchez et al. 1999; Moscat, Diaz-Meco et al. 2007). Along 
with PB1 domain, the TB domain is responsible for interacting with tumor necrosis factor 
associated receptor-6 (TRAF6), a lysine (K) 63 E3 ligase. p62 self-oligmerization 
promotes TRAF6 interaction and K63 polyubiquitination, which leads to NF-κB 
activation and subsequent inflammation response (Sanz, Diaz-Meco et al. 2000; 
Moscat, Diaz-Meco et al. 2006; Duran, Linares et al. 2008; Moscat and Diaz-Meco 
2009). The Kelch-like ECH-associated protein 1 (Keap1) interacting domain (KIR) in the 
c-terminus mediates the stress response in p62 accumulation by interacting with the 
Kelch-repeat domain of Keap1, dissociating it from nuclear factor (erythroid-derived 2)-
like 2 (Nrf2), a transcription factor and allowing Nrf2 to translocate to the nucleus to 
activate stress response gene transcription (Jain, Lamark et al. 2010). Interestingly, 
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Nrf2 has been implicated in tumorigenesis via its antioxidant program (DeNicola, 
Karreth et al. 2011).Disruption in the autophagy degradation process promotes  p62 
accumulation and  p62 positive protein aggregates.  
p62 is an autophagy substrate and also serves as an autophagy receptor to bind 
to  ubiquitinated proteins or organelles to promote their degradation by autophagy 
(Bjorkoy, Lamark et al. 2005; Komatsu, Waguri et al. 2007). p62 binds with ubiquitinated 
proteins through its ubiquitin associated domain (UBA) in the c-terminus (Donaldson, Li 
et al. 2003). p62 also interacts with LC3 through its LC3 interacting region (LIR) in the c-
terminus (Bjorkoy, Lamark et al. 2005; Pankiv, Clausen et al. 2007; Ichimura, 
Kumanomidou et al. 2008). Therefore, the LIR enables p62 to tether ubiquitinated 
proteins to the autophagosomal membrane via its direct interaction with LC3 (Ichimura, 
Kumanomidou et al. 2008; Komatsu and Ichimura 2010). Accumulation of p62 has been 
implicated in tumorigenesis and hepatocellular carcinoma but the mechanism is not 
clear (Duran, Linares et al. 2008; Mathew, Karp et al. 2009; Inami, Waguri et al. 2011; 
Takamura, Komatsu et al. 2011). Furthermore, a couple of groups have shown that 
knockout of p62 attenuates liver inflammation, hepatomegaly, and the rate of tumor 
growth in liver-specific Atg7 knockout mice (Komatsu, Waguri et al. 2007; Takamura, 
Komatsu et al. 2011). This suggests that p62 promotes tumorigenesis when autophagy 
is suppressed. Mechanistically, the persistent activation of Nrf2 due to p62 
accumulation is most likely the key mechanism to promote liver tumorigenesis because 
further deletion of Nrf2 completely abolished liver tumorigenesis in liver-specific Atg5 





















 p62 structure, binding partners and functions.  
p62 has six distinct functional domains: PB1, ZZ, TB, LIR, KIR and UBA. PB1 domain 
self- and hetero-oligomerizes with other PB1 containing proteins, such as NBR1, 
ERK and aPKC. p62 binds with RIP at ZZ zinc finger region, and TRAF6 at TB 
domain, which regulates NF-kB activation. p62 interacts with LC3 through the LIR, 
and Keap1 through the KIR. The c-terminal UBA domain of p62 binds to ubiquitin.  
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1.13 Alcoholic liver disease is a major contributor of liver diseases worldwide 
 Alcohol consumption and abuse lead to alcoholic liver disease (ALD), a major 
contributor of liver diseases and mortality both in the United States and worldwide 
(Rehm, Mathers et al. 2009; Gao and Bataller 2011). ALD is characterized by the 
development of steatosis in early stages and could progress to fibrosis, alcoholic 
hepatitis, cirrhosis, and hepatocellular carcinoma (Figure 1.8) (Ding, Manley et al. 2011; 
Gao and Bataller 2011). ALD also induces hepatic metabolic changes, increases 
oxidative stress, and alters lipid metabolism resulting in the accumulation of lipid 
droplets (Ding, Manley et al. 2011). Importantly, 95% of alcoholic patients develop 
steatosis; however, only 20 to 40% of patients progress to fibrosis and only a very small 
portion of patients exhibit a more severe form of ALD such as cirrhosis and HCC (Gao 
and Bataller 2011).  This brings on the question of why most of alcoholics are protected 
from severe forms of ALD? While it is still not clear, several mechanisms have been 
suggested that may be responsible for the variations observed among different drinkers. 
Indeed, ALD usually manifests in synergy with other risk factors such as sex, obesity, 
dietary factors, genetic factors, smoking and viral hepatitis (Wilfred de Alwis and Day 
2007; Tsukamoto, Machida et al. 2009; O'Shea, Dasarathy et al. 2010).  
Women are twice as sensitive to ethanol-induced hepatotoxicity and may 
develop ALD in shorter duration and lesser doses of alcohol than men (Sato, Lindros et 
al. 2001; O'Shea, Dasarathy et al. 2010). Women and men both displayed gender 
differences in the pharmacokinetics of alcohol mediated by several possible causes 
including the differences in relative amount of gastric alcohol dehydrogenase, higher 
rate of body fat in women, and change in the absorption of alcohol with menstrual cycle 
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(Frezza, di Padova et al. 1990; Sato, Lindros et al. 2001; O'Shea, Dasarathy et al. 
2010). Race and ethnicity also may influence the outcome of alcohol-mediated liver 
injury (Stewart 2002). Alcoholic cirrhosis rates are higher in African-American and 
Hispanic males than Caucasian males. Moreover, the mortality rate from ALD is highest 
in Hispanic males (Stinson, Grant et al. 2001). The differences in alcohol consumption 
appear not to be related to the racial and ethnic differences in mortality 
(Wickramasinghe, Corridan et al. 1995). Therefore, genetic factors play a role in 
alcoholism and ALD. Children of alcoholics raised in adopted families are more 
predisposed to alcoholism in comparison to adopted children of nonalcoholics 
(Goodwin, Schulsinger et al. 1973). Furthermore, twin studies showed that monozygotic 
twins are twice as likely to drink as dizygotic twins and alcoholic cirrhosis prevalence is 
higher in monozygotic twins than dizygotic twins (Kaprio, Koskenvuo et al. 1987; Reed, 
Page et al. 1996). Genetic polymorphisms of alcohol metabolizing genes including 
alcohol dehydrogenase, acetaldehyde dehydrogenase, and cytochrome P450s also 
have been associated with ALD (O'Shea, Dasarathy et al. 2010). Moreover, genes 
involved with the regulation of endotoxin-mediated release of cytokines have been 
associated with ALD (O'Shea, Dasarathy et al. 2010). Another possible explanation is 
that ethanol may also trigger the cellular defense mechanisms such as autophagy and 
increased expression of interleukin-22 (IL-22) in addition to its detrimental effects (Ki, 




















 Pathogenesis of ALD.  
95% of alcoholics develop steatosis, however, only 35% of drinkers develops more 
severe forms of ALD including fibrosis, cirrhosis, alcoholic hepatitis, and HCC.  
(Gao and Bataller 2011). Reprinted from Alcoholic Liver Disease: Pathogenesis and 
New Therapeutic Targets, Volume 141 Issue 5, Gao and Bataller, Gastroenterology, 
1572-1585., Copyright (2011), with permission from Elsevier.  
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1.14 Activation of autophagy alleviates alcohol-induced liver injury 
As previously discussed, autophagy is an evolutionarily conserved catabolic 
process responsible for the degradation of cellular proteins and damaged organelles, 
and is a cellular protective mechanism in response to stress (Ding, Manley et al. 2011). 
Liver enlargement known as hepatomegaly is a common response to alcohol toxicity in 
both alcohol-fed animals and alcoholics. Alcohol-induced hepatomegaly is a result of 
protein and lipid accumulation (Baraona, Leo et al. 1975).  Chronically alcohol-fed rat 
livers display normal protein synthesis activity; however, the rate of protein degradation 
is decreased by around 40% in the livers of alcohol-fed animals (Donohue, Sorrell et al. 
1987; Donohue, Zetterman et al. 1989; Dolganiuc, Thomes et al. 2012). Moreover, 
alcohol administration disrupts lysosomal proteolytic activity by alkalinizing the 
lysosomal interior and disrupting the trafficking of cathepsins to lysosomes (Kharbanda, 
McVicker et al. 1996; Kharbanda, McVicker et al. 1997). These findings may suggest 
that autophagy could be impaired in chronic alcohol consumption conditions although 
this is still controversial. However, acute alcohol exposure induces autophagy to 
selectively promote the degradation of lipid droplets and damaged mitochondria (Ding, 
Li et al. 2011). Indeed, pharmacologic activation of autophagy has been shown to 
alleviate alcohol-induced steatosis and hepatotoxicity, whereas pharmacologic inhibition 
of autophagy exacerbates alcohol-induced liver injury (Figure 1.9) (Ding, Li et al. 2010; 










Pharmacological Activation of Autophagy Alleviates Ethanol-Induced 
Steatosis.  
Ethanol induces steatosis, and pharmacological inhibition of autophagy by 
chloroquine exacerbates ethanol-induced steatosis, whereas activation of autophagy 




1.15 FXR may have a protective role against alcohol-induced liver injury 
Alcohol consumption induces hepatic metabolic changes, increases oxidative 
stress, and alters lipid metabolism, which result in liver injury. Moreover, alcohol may 
induce cholestasis in all stages of ALD (Tung and Carithers 1999). Indeed, chronic 
alcohol consumption in rats increases total and unconjugated serum bile acids and 
alters the bile acid profiles in the intestines (Xie, Zhong et al. 2013). Chronic alcohol 
consumption induces acetylation of FXR resulting in inactivation of FXR and 
subsequent increased hepatic bile acid levels in mouse. Indeed, pharmacological 
activation of FXR by a specific FXR agonist, WAY-362450, attentuates ethanol-induced 
liver injury, steatosis and inflammation (Wu, Zhu et al. 2014). Furthermore, alcohol 
consumption induces the expression of gene encoding bile acid synthesis enzyme 
(CYP7A1) and basolateral bile acid transporters (Ostα and β) in rat livers (Xie, Zhong et 
al. 2013). Bile acids also regulate alcohol metabolism by inducing class I alcohol 
dehydrogenase (ADH1) gene expression through activation of FXR in human 
hepatocytes, but not in rodent hepatocytes. Human ADH1A and ADH1B proximal 
promoter regions contain putative FXR response elements (Langhi, Pedraz-Cuesta et 
al. 2013). These recent studies reveal that bile acid metabolism and ethanol metabolism 
cross-talk by regulating each other.  
Altered hydrophobicity in bile acid pools by CDCA feeding has been shown to 
aggravate liver injury induced by chronic alcohol feeding. CDCA feeding plus chronic 
ethanol drinking in mice leads to increased hepatic triglycerides and elevated serum 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST), markers of liver 
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injury (Montet, Oliva et al. 2002). The mechanism of liver injury in CDCA feeding plus 
chronic ethanol drinking is not known.   
1.16 FoxO3a, a transcription factor, upregulates autophagy related gene 
transcription in response to ethanol 
Forkhead box O3a (FoxO3a), a member of FoxO family of transcription factors, is 
involved with a variety of cellular processes including proliferation, apoptosis, stress 
resistance, metabolic responses, and autophagy (Birkenkamp and Coffer 2003; van der 
Horst and Burgering 2007; van der Vos and Coffer 2008).  The FoxO3a structure 
contains a Forkhead DNA binding domain, two nuclear localization sequences (NLS) 
and a nuclear export sequence (NES) in the c-terminus (Figure 1.10) (Calnan and 
Brunet 2008). Activation and repression of FoxO3a is regulated by an intricate system 
involving multiple signaling pathways, co-factors, and multiple binding partners. 
Furthermore, FoxO3a activation is regulated by multiple posttranslational modifications 
including phosphorylation, acetylation, and ubiquitination (Figure 1.10).  Akt is identified 
to be the key regulator of FoxO3a activation, in which Akt phosphorylation enhances 
FoxO3a binding to the 14-3-3 protein resulting in cytoplasmic accumulation and 
subsequent inactivation of FoxO3a (Tzivion, Dobson et al. 2011). Conversely, 
dephosphorylation at sites threonine 32 and serine 253 by protein phosphatase 2A 
(PPA2) promotes nuclear FoxO3a accumulation and subsequent activation of Foxo3a 
(Singh, Ye et al. 2010). Casein kinase 1 (CK1), inhibitor of nuclear factor kappa B 
kinase subunit beta (IKKβ) and extracellular-signal-regulated kinase (ERK) all 
phosphorylate FoxO3a resulting in the inhibition of FoxO3a activation (Hu, Lee et al. 
2004; Calnan and Brunet 2008; Yang, Zong et al. 2008). Conversely, the 
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phosphorylation of FoxO3a by AMPK at serine residues 413 and 588 induces FoxO3a 
activation (Greer, Oskoui et al. 2007). Acetylation of FoxO3a by cAMP response 
element binding-binding protein (CBP), p300, and p300/CBP-associated factor (PCAF) 
results in inactivation of FoxO3a. Interestingly, deacetylation of FoxO3a by Sirt1, a 
NAD-dependent deacetylase, results in FoxO3a ubiquitination and degradation (Wang, 
Chan et al. 2012).  In addition, it has been found that Sirt1 has dual effects on FoxO3a-
mediated gene expression.  Sirt1 enhances FoxO3a-induced expression of cell cycle 
arrest and oxidative stress resistance genes, but inhibits FoxO3a-induced expression of 
apoptotic genes (Brunet, Sweeney et al. 2004). These results suggest that Sirt1-
mediated acetylation of FoxO3a may determine the specificity of FoxO3a-induced gene 
expression. Finally, ubiquitination of FoxO3a by E3 ligases, S-phase kinase-associated 
protein 2 (Skp2), and murine double minute 2 (MDM2), targets FoxO3a toward the 
ubiquitin-proteasome system for degradation (Huang and Tindall 2011; Wang, Chan et 
al. 2012).  
Multiple binding partners also regulate FoxO3a activation and enable FoxO3a to 
confer a wide range of transcriptional responses (van der Vos and Coffer 2008). FoxO 
family members have been shown to bind with the following nuclear receptors: 
constitutive androgen receptor (CAR) (Kodama, Koike et al. 2004), hepatic nuclear 
factor-4 (HNF4) (Hirota, Daitoku et al. 2003), peroxisome proliferator-activated 
receptors alpha and gamma (PPARα and PPARγ) (Dowell, Otto et al. 2003; Qu, Su et 
al. 2007), pregnane X receptor (PXR) (Kodama, Koike et al. 2004), and retinoic acid 
receptor (RAR) (Zhao, Herrera et al. 2001) and influence both nuclear receptor-
mediated and FoxO-mediated gene transcription. The interaction of FoxO with HNF4 
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and PPARα suppresses nuclear receptor-mediated transcription. In contrast, FoxO 
interacts with CAR, PPARγ, PXR and RAR to induce nuclear receptor-mediated 
transcription. FoxO-mediated transcription is suppressed by the interaction with 
PPARα/γ and CAR (van der Vos and Coffer 2008). FoxO3a possesses a LxxLL motif in 
the c-terminal of the Forkhead DNA-binding domain and may interact with nuclear 
receptors through its LxxLL motif (Zhao, Herrera et al. 2001). Moreover, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) has been reported 
to interact with FoxO3 and inhibit the transcription of FoxO3a target genes in skeletal 
muscles (Sandri, Lin et al. 2006). In contrast, PGC-1α interacts with FoxO3a but 
increases the expression of FoxO3a-dependent oxidative stress protection genes in the 
vascular endothelium (Olmos, Valle et al. 2009). These data may suggest that the role 
of FoxO3a and PGC-1α interaction could be tissue-specific. The role of FoxO3a and 
PGC-1α interaction in FoxO3a-dependent gene transcription in liver has not been 
studied.  
The activation of autophagy is another cellular protective function of FoxO3a. 
FoxO3a has been shown to activate both autophagic-lysosomal pathway and ubiquitin-
proteasomal system in skeletal muscles. In addition to Akt pathway-mediated induction 
of autophagy, FoxO3a induces the expression of autophagy-related genes and 
subsequent induction of autophagy independent of mTOR (Mammucari, Milan et al. 
2007; Zhao, Brault et al. 2007) Activation of autophagy by FoxO3a also has been 
verified in cardiomyocytes (Sengupta, Molkentin et al. 2009) and hematopoietic stem 
cells (Warr, Binnewies et al. 2013). Furthermore, our lab recently demonstrated that 
acute ethanol-induced autophagy in mouse livers is mediated by the activation of 
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FoxO3a (Ni, Du et al. 2013).  Acute ethanol treatment promotes nuclear FoxO3a 
translocation by attenuating Akt-mediated phosphorylation of FoxO3a at serine 253 (Ni, 
Du et al. 2013). Serine 253 phosphorylation of FoxO3a enhances FoxO3a binding with 
the 14-3-3 protein and targets FoxO3a for degradation by the ubiquitin-proteasomal 
system (Tzivion, Dobson et al. 2011).    
Sirt1 is responsible for deacetylating FoxO3a and tips the balance by shifting the 
FoxO3a response toward inducing cell cycle arrest and oxidative stress resistance and 
away from induced cell death (Brunet, Sweeney et al. 2004). Acute ethanol exposure 
decreases Sirt1 protein levels by increasing the NADH/NAD+ radio and subsequently 
increases the acetylation of FoxO3a. Interestingly, resveratrol, a Sirt1 agonist, further 
increases ethanol-induced autophagy related gene expressions (Ni, Du et al. 2013). 
Altogether, the data suggest that the acetylation of FoxO3a may determine the binding 
affinity to the binding sites in the promoter regions of autophagy-related genes.  
Furthermore, FoxO3a has been found to be hepatoprotective against ethanol-induced 
liver steatosis and injury, and FoxO3a deficient mice display enhanced liver injury, 
inflammation, and steatosis upon acute and chronic ethanol exposure (Ni, Du et al. 































Structure of FoxO3a and Its Post-Translational Modification Sites.  
FoxO3a has a DNA binding forkhead site at amino acids 148-257, two nuclear 
localization sequences at amino acids 249-251 and 269-271, and a nuclear export 
site at amino acids 386-396.  The c-terminus of FoxO3a also acts as a 
transactivation domain. FoxO3a has multiple phosphorylation sites that can be 
phosphorylated by multiple enzymes including Akt, CK1, IKKβ, AMPK, and ERK 
pathways. Furthermore, FoxO3a also can be acetylated by CBP/p300, PCAF, and an 
unknown enzyme via oxidative stress. Sirt1 deacetylates FoxO3a. Skp2 ubiquitinates 
FoxO3a and targets FoxO3a for proteasomal degradation. MDM2 also ubiquitinates 















CHAPTER 2:  













2.1 Specific Aim 1: Bile acids, in particular deoxycholic acid (DCA), have been 
reported to increase the GFP-LC3 puncta count in primary rodent hepatocytes (Zhang, 
Park et al. 2008). Our preliminary data showed that LC3-II and p62 protein expressions 
were consistently increased in bile acids-treated primary hepatocytes. Mice deficient in 
autophagy develop spontaneous liver tumors. FXR KO mice also develop spontaneous 
liver tumors not unlike autophagy deficient mice. Furthermore, my preliminary data have 
shown that FXR KO mice livers exhibit increased LC3-II and p62 protein levels. I 
hypothesize that bile acids suppress autophagy in hepatocytes. To determine the 
role and mechanisms by which bile acids regulate autophagy, I examined the following 






























Diagram of the Specific Aim 1. Aim 1a is to determine if bile acids inhibits 
autophagy. Aim 1b is to investigate the effects of bile acids on autophagosomal-
lysosomal fusion, a required event in autophagic degradation process. Aim 2c is to 
examine the effects of bile acids on lysosomal function and integrity. Bile acids are 
hypothesized to suppress autophagy in hepatocytes.  
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2.2 Aim 1a: To determine the effects of bile acids on autophagy.  
In my preliminary studies, CA and CDCA both consistently increased the p62 and LC3-II 
protein levels, suggesting that bile acids may modulate autophagy. In addition, data 
from the autophagy flux assays suggested that bile acids suppress autophagy. I 
hypothesize that bile acids impair autophagy flux.  
2.3 Aim 1b: To examine the effects of bile acids on fusion of autophagosome with 
lysosome.  
Accumulation of LC3-II may occur from either inhibition in the degradation process or 
increase in the formation of autophagosomes as a result of autophagy induction. The 
autophagy flux assay from the preliminary data suggests that bile acids suppress 
autophagy in the late stage due to the accumulation of LC3-II proteins. Late stage 
inhibition of autophagy may occur from either the inhibition of the autophagosomal-
lysosomal fusion process or impaired lysosomal function. I hypothesize that bile acids 
impair the autophagosomal-lysosomal fusion process.  
2.4 Aim 1c: To determine the effects of bile acids on the lysosomal functions, the 
downstream process of autophagy.  
Hydrophobic bile acids exert toxic effects and trigger apoptosis. It has been shown that 
lysosomal membrane permeabilization results in apoptosis. Bile acids possibly mediate 
the release of cathepsins from the lysosomes and induce the apoptotic pathway. 
Another possibility is that the bile acids increase pH inside the lysosomes by either 
lysosome membrane permeabilization or disrupting the pH homeostasis mediated by 
proton pumping ATPases, chloride channels, and cAMP regulated chloride channels. I 
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hypothesize that hydrophobic bile acids disrupt the lysosomal function by 
initiating the lysosomal membrane permeabilization event and the subsequent 
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The portions of this section are reproduced from following publication with 
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Bile acids (BAs) are amphipathic molecules synthesized in the liver and are 
important for the intestinal absorption of dietary fats and fat-soluble vitamins (Chiang 
2003). However, during cholestasis, BAs are accumulated in the liver, resulting in liver 
injury by inducing cell death (Schoemaker, Gommans et al. 2003). Hydrophobic BAs, 
such as cholic acid (CA) and chenodeoxycholic acid (CDCA), are known to be toxic in 
cultured hepatocytes. The mechanisms for BA-induced toxicity are not fully understood, 
but activation of Fas death receptor, oxidative stress and endoplasmic reticulum stress 
may be involved (Faubion, Guicciardi et al. 1999; Yerushalmi, Dahl et al. 2001; Tamaki, 
Hatano et al. 2008). 
Autophagy is a cellular lysosomal degradation pathway that degrades cellular 
proteins and damaged organelles to promote cell survival in response to a variety of 
stresses. The autophagy process is characterized by the formation of double-membrane 
autophagosomes. Autophagosomes fuse with lysosomes to form autolysosomes where 
the autophagosome-enwrapped contents are degraded (Mizushima 2007). The 
mechanisms by which autophagosomes fuse with lysosomes are not clear, but soluble 
N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, the 
small GTP binding protein Rab7, and the homotypic fusion and vacuole protein sorting 
(HOPS) complex may play a role in regulating the fusion of autophagosomes with 
lysosomes in mammalian cells (Jager, Bucci et al. 2004; Furuta, Fujita et al. 2010; 
Itakura, Kishi-Itakura et al. 2012). 
Autophagy is a dynamic process, and the ubiquitin-like protein, microtubule-
associated protein 1 light chain 3 (LC3), is thought to be important for isolation 
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membrane elongation and eventual closure of the autophagosomal membrane 
(Nakatogawa, Ichimura et al. 2007). LC3 is conjugated to phosphatidylethanolamine 
(PE) (called LC3-II) and targets the autophagosomal membrane (Kabeya, Mizushima et 
al. 2000). The LC3-II on the outer autolysosome membrane is de-conjugated and 
removed by the cysteine protease Atg4B and recycled, while the LC3-II on the inner 
membrane together with the enveloped cytosolic contents are degraded by the 
lysosome (Kirisako, Ichimura et al. 2000). Thus, the accumulation of LC3-II could be 
due to either the induction of autophagy or the inhibition of lysosomal functions and/or 
the defect of fusion of autophagosomes with lysosomes, which leads to impaired 
degradation of LC3-II (Klionsky, Abdalla et al. 2012).  This dynamic process of 
autophagosome formation, delivery of autophagosomal cargo to lysosomes and 
completion of lysosomal degradation of cargo is known as autophagic flux. Therefore, 
autophagic flux is a more accurate indicator of autophagic process than simple 
measurement of the number of autophagosomes (Mizushima, Yoshimori et al. 2010). 
Autophagy also selectively degrades some specific autophagy substrates such as 
sequestosome 1 (SQSTM1)/p62, which accumulate in autophagy-deficient cells or 
mouse liver (Komatsu, Waguri et al. 2007; Kirkin, Lamark et al. 2009; Ni, Boggess et al. 
2012). Thus, determination of LC3-II and p62 levels in the presence or absence of 
lysosomal inhibitors, such as chloroquine (CQ), has been widely used to monitor 
autophagic flux (Klionsky, Abdalla et al. 2012). 
Farnesoid X receptor (FXR) is a member of the nuclear hormone receptor 
superfamily and highly expressed in the liver, intestine, kidney and adrenal gland 
(Forman, Goode et al. 1995; Lu, Repa et al. 2001). FXR plays a critical role in 
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maintaining cholesterol and BA homeostasis based on studies from FXR knockout (KO) 
mice and FXR agonists (Sinal, Tohkin et al. 2000; Kim, Morimura et al. 2007). BAs 
including CA and CDCA are very potent endogenous ligands of FXR. FXR KO mice 
have increased hepatic apoptosis, inflammation, compensatory proliferation and 
hepatomegaly, and spontaneous liver tumors in aging mice (Kim, Morimura et al. 2007; 
Yang, Huang et al. 2007). All these hepatic pathology in FXR KO mice echo those 
observed in liver-specific Atg7 or Atg5 KO mice, animals with impaired autophagy in the 
liver (Inami, Waguri et al. 2011; Takamura, Komatsu et al. 2011). While the exact 
mechanisms by which FXR KO mice develop these phenotypes in the liver are under 
diligent investigation, FXR KO mice have increased concentrations of BAs in liver and 
serum, which is suggested to partially responsible for promoting liver tumor formation in 
mice (Kim, Morimura et al. 2007; Yang, Huang et al. 2007). We thus hypothesized that 
FXR KO mice have impaired autophagy in the liver, which could be due to increased 
concentrations of BAs. Here, we report that whole body, but not liver-specific, FXR KO 
mice had increased accumulation of p62 and LC3-II proteins in the liver, suggesting 
autophagy is impaired in the livers of whole body FXR KO mice. Furthermore, we found 
that BAs decreased Rab7 expression and its recruitment to autophagosomes, resulting 
in impaired autophagosomal-lysosomal fusion and subsequent decreased autophagic 







3.2 MATERIALS AND METHODS 
Reagents and Antibodies.  CA, CDCA, taurocholic acid (TCA), deoxycholic acid 
(DCA), and ursodeoxycholic acid (UDCA) were obtained from Sigma-Aldrich. All cell 
culture materials were obtained from Invitrogen. Antibodies used in the study were 
cleaved caspase-3 (Cell Signaling Cat. #9661), GFP (Santa Cruz Biotechnology, Cat. # 
sc-9996), p62 (Abnova, Cat. # H00008878-M01), β-Actin (Sigma, Cat. # a5541), Atg5 
(MBL, Cat# PM050), GAPDH (Cell Signaling, Cat. # 2118), Rab7 (Cell Signaling Cat. # 
9367), and LAMP-1 and LAMP-2 (Developmental Studies Hybridoma Bank, Iowa City, 
IA, Cat. # 1D4B and Cat. # ABL-93).  The rabbit polyclonal anti-LC3B antibody was 
described previously (Ding, Ni et al. 2009). The secondary antibodies used in this study 
for immunoblotting analysis were HRP-conjugated goat anti-mouse (Jackson 
ImmunoResearch, Cat. #115-035-062), rabbit (Jackson ImmunoResearch, Cat. #111-
035-045), and rat (Jackson ImmunoResearch Cat. # 111-035-143) antibodies. The 
secondary antibodies used for immunostaining were Cy3-conjugated goat anti-rabbit 
(Jackson ImmunoResearch Cat. # 111-165-144), Cy3-conjugated goat anti-rat (Jackson 
ImmunoResearch Cat. #112-165-143), DyLightTM conjugated goat anti-mouse (Jackson 
ImmunoResearch Cat. #115-505-146), and AlexaFluor 488 goat anti-rabbit antibodies 
(Invitrogen).  
Animals and Primary Mouse Hepatocyte Culture. Wild type (WT) C57BL/6J, FXR 
KO, FXR flox/flox (Albumin Cre negative or positive) mice (FXR fl/fl, Alb Cre- or FXR fl/fl, 
Alb Cre+) were housed with free access to water and chow. All animals received 
humane care. All procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Kansas Medical Center.  Mouse hepatocytes isolated 
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from WT and FXR-/- mice were described previously (Ding, Ni et al. 2004), and cultured 
in William’s medium E with 10% fetal bovine serum, 2 mM glutamine as well as routine 
antibiotic supplements for 2 h for attachment. Cells were then cultured in the same 
medium without serum overnight before treatment.   All cells were maintained in a 37°C 
incubator with 5% CO2.   
Viability Assay.   
Primary hepatocytes were seeded in a 12 well plate (1 x 105 per well) and cells were 
treated with various concentrations (50, 100, or 200 µM) of BAs for 6 or 24 h. Cells were 
stained with propidium iodide (1 µg/mL) and Hoechst 33342 (1 µg/mL) followed by 
fluorescence microscopy. Both apoptotic (condensed and fragmented nuclei) and PI 
positive cells were considered dead cells, and the percentage of viable cells was 
calculated. More than 300 cells were counted from each experiment and data are 
means± SD from 3 independent experiments 
Fluorescence, Confocal and Electron Microscopy. 
Adenovirus expressing GFP-LC3 was used as described previously (Gao, Ding et al. 
2008). To examine autophagy, primary hepatocytes were seeded in a 12 well-plate (1 x 
105 per well) on a cover slide and infected with adenovirus-GFP-LC3 (100 viral particles 
per cell) overnight.  Cells were treated with CA (100 µM), CDCA (100 µM) and TCA 
(100 µM) in the presence or absence of chloroquine (CQ, 20 µM) for 6 h.  For some 
experiments, hepatocytes were transfected with RFP-GFP-LC3 using TurboFect 
(Fermentas) for 24 h followed by designated treatments. After treatments, cells were 
fixed with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) for 2 h at 
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room temperature or kept at 4°C for microscopy. Fluorescence images were acquired 
under a Nikon Eclipse 200 fluorescence microscope with MetaMorph software. For the 
immunostaining assay, fixed primary hepatocytes were immunostained with anti-Lamp1 
or anti-Rab7 antibodies followed by Cy3-conjugated secondary antibody and Hoechst 
33342 staining as previously described. Cell images were then obtained using a Leica 
Confocal microscope (TCS SPE model). For electron microscopy (EM), hepatocytes 
were fixed with 2.5% glutaraldehyde in 0.1 mol/L sodium cacodylate buffer (pH 7.4), 
followed by 1% OsO4. After dehydration, thin sections were cut and stained with uranyl 
acetate and lead citrate. Digital images were obtained using a JEM 1016CX electron 
microscope.  
DQ-bovine serum albumin (BSA) Assay. Primary cultured mouse hepatocytes were 
first loaded with DQ-BSA (10 µg/mL, Invitrogen) 1 hr prior to treatment with various BAs 
and CQ for another 6 h. DQ-BSA is a derivative of BSA that is labeled to such a high 
degree with BODIPY® dyes, BODIPY TR-X, that the dye is strongly self-quenched. 
Proteolysis of the BODIPY-BSA conjugate results in de-quenching and the released 
protein fragment that contains isolated red fluorophore is brightly fluorescent that has 
excitation and emission maxima of 590 nm and 620 nm. Following treatment, 
hepatocytes were washed with PBS to remove excessive DQ-BSA and lysed in 1% 
Triton X-100 in 50 mM Tris-HCL (pH 8.8) solution. Fluorescence intensity of the lysates 
was quantified using a Tecan Infinite M200 Pro plate reader (excitation: 590 and 
emission: 620).  
RNA Isolation and Real-Time qPCR. RNA was isolated from cultured hepatocytes and 
livers using Qiagen RNeasy kit (Qiagen, Valencia, CA) and reverse transcribed into 
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cDNA by RevertAid reverse transcriptase (Fermentas). Real-time PCR was performed 
on an Applied Biosystems Prism 7900HT real-time PCR instrument (ABI, Foster City, 
CA) using Maxima SYBR green/rox qPCR reagents (Fermentas). Primer sequences 
were as follows:  β-actin forward: 5’ – TGT TAC CAA CTG GGA CGA CA – 3’; β-actin 
reverse: 5’ – GGG GTG TTG AAG GTC TCA AA – 3’; Map1lc3b forward: 5’ – 
CCGAGAAGACCTTCAAGCAG – 3’; Map1lc3b reverse: 5’ – 
ACACTTCGGAGATGGGAGTG – 3’; Sqstm1/p62 forward: 5’ – AGA ATG TGG GGG 
AGA GTG TG– 3’; Sqstm1/p62 reverse: 5’ – TCG TCT CCT CCT GAG CAG TT – 3’; 
Shp forward: 5’ – CTG CAG GTC GTC CGA CTA TT – 3’; and Shp reverse: 5’ – ACC 
TCG AAG GTC ACA GCA TC – 3’. 
 
Cathepsin B and Proteasome Activity Assay.  Specific fluorescence substrates were 
used to measure Cathepsin B and proteasome activities. Primary cultured mouse 
hepatocytes were treated with CA (100 µM), CDCA (100 µM), TCA (100 µM), CQ (20 
µM) or E64D (10 µM) for 6 h.  After treatment, cells were lysed in M2 buffer (50 mM Tris 
pH 7.5, 130 mM NaCl, 10% glycerol, 0.5% NP-40, 0.5 mM EDTA, and 0.5 mM EGTA in 
dH2O) without protease inhibitors. To determine cathepsin B activity, protein lysates (15 
µg) were incubated with 2 µM z-RR-AMC (Calbiochem # 219392) in assay buffer (10 
mM HEPES-NaOH pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM 
KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM PMSF, and 1 mM DTT 
in dH2O) for 1 hr, and fluorescence intensity was determined using a Tecan Infinite 
M200 Pro plate reader (excitation: 380 and emission: 460). To determine proteasome 
activity, protein lysates (10 µg) were incubated with 0.65 µM Suc-LLVY-AMC 
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(Calbiochem #539142) in assay buffer (50 mM Tris pH 7.5, 25 mM KCl, 10 mM NaCl, 
and1mM MgCl2) for 1 hr, and the fluorescence intensity was determined using a Tecan 
Infinite M200 Pro plate reader (excitation: 380 nm and emission: 460 nm).  
 Immunoblot Analysis. Cells were washed in PBS and lysed in RIPA buffer.  Twenty 
micrograms of protein from each sample were separated by SDS-PAGE and transferred 
to PVDF membranes.  The membranes were stained with primary antibodies followed 
by secondary horseradish peroxidase-conjugated antibodies. The membranes were 
further developed with SuperSignal West Pico chemiluminescent substrate (Pierce). 
Densitometry analysis was performed using Un-Scan-It software and further normalized 
with β-actin. 
Statistical Analysis. All experimental data were expressed as mean ± SE and 
subjected to a Student t-test or one-way analysis of variance with Holm-Sidak post hoc 















Increased Accumulation of Hepatic p62 and LC3-II Proteins in FXR KO Mice  
 Since mice with autophagy-deficiency in the liver and FXR KO mice all develop 
spontaneous liver tumors, we hypothesized that FXR KO mice may have impaired 
autophagy in the liver. Indeed, similar to liver-specific Atg7 or Atg5 KO mice, both 3 and 
6 month old FXR KO mice had increased accumulation of p62 proteins in the liver 
(Figure 3.1A). Interestingly, hepatic LC3-II protein levels were also increased in 3 and 6 
month old FXR KO mice compared to their age-matched WT controls. In contrast, there 
was no difference between WT and FXR KO mice for other autophagy proteins 
responsible for regulation of upstream events for the formation of autophagosomes, 
such as Atg5-Atg12 and Beclin-1. Moreover, there was no difference in hepatic mRNA 
levels of Sqstm1/p62 or Map1lc3b (Microtubule-associated protein 1 light chain 3 beta) 
between WT and FXR KO mice, whereas the level of Shp, a FXR target gene, was 
dramatically diminished in FXR KO mice (Figure 3.1B). It is known that FXR KO mice 
have increased hepatic and serum BAs (Sinal, Tohkin et al. 2000; Kim, Morimura et al. 
2007), we next determined whether the increased levels of p62 and LC3-II was due to 
the increased BAs or the lack of FXR.  We thus determined the levels of p62 and LC3-II 
in liver-specific FXR KO mice, which we previously showed that these mice had normal 
hepatic BAs (Borude, Edwards et al. 2012). No significant differences were found for 
p62, LC3-II, Atg5-Atg12 and Beclin-1 protein expression between liver-specific FXR KO 
mice and their WT littermates (Figure 3.1C). Altogether, these data indicate that FXR 
KO mice had increased hepatic levels of p62 and LC3-II, which is less likely due to the 



























































Increased p62 and LC3-II protein expression in FXR KO mouse livers. 
(A) Total lysates from 3 and 6 month old FXR+/+ and FXR-/- mouse livers were 
subjected to immunoblot analysis. Digital data are densitometry analysis and 
presented as a ratio of wild type mice (n=4-5). (B) mRNA was isolated from 3 months 
old FXR+/+ and FXR-/- KO mouse livers and qRT-PCR was performed. The gene 
expression levels were normalized to β-actin and shown as fold increase over wild 
type mice (n=6-7). (C) Total liver lysates from 3 months old FXRfl/fl:Alb-Cre- and 
FXRfl/fl:Alb Cre+  mouse livers were subjected to immunoblot and densitometry 
analysis .  
 
Figure 3.1 (cont’d) 
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Accumulation of Hepatic p62 Protein in Intrahepatic and Extrahepatic Cholestasis 
Mouse Models  
We demonstrated that whole body FXR KO, but not hepatic specific FXR KO mice have 
p62 and LC3-II protein accumulation, which suggests bile acids impair autophagy. To 
confirm that bile acids, not FXR deficiency, inhibit autophagy, we examined the p62 and 
LC3-II protein levels in other cholestasic mouse models. α-naphthylisothiocyanate 
(ANIT) is a widely used chemical to induce intrahepatic cholestasis in rodents (Becker 
and Plaa 1965; Capizzo and Roberts 1970). ANIT is detoxified in the liver by glutathione 
(GSH) conjugation, and ANIT-GSH compound is transported into the bile, where ANIT 
is dissociated from GSH. The free ANIT then selectively damages bile-duct epithelial 
cells resulting in cholangitis, and subsequent intrahepatic cholestasis (Carpenter-Deyo, 
Marchand et al. 1991; Dietrich, Ottenhoff et al. 2001). In the ANIT model, we found that 
ANIT induces p62, but not LC3-II, protein expression by 1.5 fold at both 24 and 48 
hours after ANIT administration (Figure 3.2A). Bile duct ligation (BDL) is the most 
common used model for extrahepatic cholestasis since it closely mimics the 
pathogenesis of obstructive cholestasis (Schaffner, Bacchin et al. 1971).  BDL induces 
hepatic and serum bile acids accumulation at 6 hours to 14 days (Kinugasa, Uchida et 
al. 1981; Zhang, Hong et al. 2012). We found similar pattern with BDL after three days 
as ANIT, in which p62 protein expression was increased two fold, but the LC3-II protein 
expression was unchanged (Figure 3.2B). The reasons for the lack of increase in LC3-
II protein level in ANIT-treated and bile duct ligated mice are not clear, but could be due 
to the differences in the models in comparison to FXR KO mice. However, it is also 
possible that the transcriptional level of p62 and LC3 could be altered in these models.  
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Nevertheless, the p62 accumulation suggests that the autophagic clearance of p62 and 














































Increased p62 protein expression in ANIT-treated and bile duct ligated mouse 
livers. 
(A) Total lysates from 0, 24 and 48 hours ANIT-treated mouse livers were subjected 
to immunoblot analysis. Digital data are densitometry analysis and presented as a 
ratio of wild type mice (n=5). (B) Mice underwent sham or bile duct ligation surgery, 
and total liver lysates were collected three days after the surgery. Total lysates were 
subjected to immunoblot analysis. Digital data are densitometry analysis and 




Hydrophobic BAs Decreased Viability in Primary Cultured Mouse Hepatocytes 
Three major primary BAs were chosen for the in vitro studies, TCA, CA and 
CDCA. TCA was chosen because serum and hepatic levels of TCA increased to around 
1 mM in BDL mice (Zhang, Hong et al. 2012). CA was chosen because serum levels of 
CA increased to 200-250 µM in mice subjected to BDL for 7 days (Marschall, Wagner et 
al. 2006), and CA has been widely used in feeding experiments in mice that show 
significant toxicity in mouse liver (Sinal, Tohkin et al. 2000; Kim, Morimura et al. 2007). 
We also chose CDCA because serum levels of CDCA increased in BDL mice, and 
CDCA increases the expression of inflammatory genes in cultured mouse hepatocytes 
(Allen, Jaeschke et al. 2011). Ursodeoxycholic acid (UDCA) is chosen because it is a 
therapeutic bile acid used in treating cholestasis, and alleviates cholestasic liver disease 
by protecting cholangiocytes against cytotoxic hydrophobic bile acids, stimulating 
hepatobiliary secretion, and protection against bile acid-induced apoptosis 
(Paumgartner and Beuers 2002). Finally, deoxycholic acid (DCA), a secondary bile acid, 
is chosen because DCA has been reported to induce GFP-LC3 puncta formation in 
rodent hepatocytes (Zhang, Park et al. 2008) and human esophageal cells (Roesly, 
Khan et al. 2012) and LC3-II protein expression in colon epithelial cells (Payne, 
Crowley-Skillicorn et al. 2009). The hydrophobicity index of BAs is 
UDCA<TCA<CA<CDCA<DCA, in which UDCA is considered as hydrophilic BA and 
TCA is considered as neutral BA (Heuman 1989; Thomas, Pellicciari et al. 2008).  
CDCA and DCA are well-known hepatotoxins and induce hepatocyte death in 
vitro (Scholmerich, Becher et al. 1984). Indeed, viability assay analysis showed that 
CDCA and DCA, but not UDCA, CA or TCA are toxic in a dose-dependent manner at 6 
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hours (Figure 3.3A). Moreover, TCA and CDCA also showed toxicity in a time-
dependent manner, but the rest of the BAs didn’t display time-dependent toxicity. More 
importantly, CQ is toxic in a time dependent manner, in which 80% of cells were viable 
at 6 hours, but only 12% of cells were viable at 24 hours (Figure 3.3B). Caspase-3 is a 
death protease that is activated when cleaved; therefore, cleaved caspase-3 is the 
hallmark of apoptosis (Porter and Janicke 1999). Indeed, CDCA induced hepatocyte 
apoptosis via caspase-3 cleavage at 100 and 200 µM, but CA did not initiate caspase-3 
cleavage. Altogether, the data show that more hydrophobic BAs induce hepatocyte 
apoptosis via cleaved caspase-3 mediated apoptosis, whereas, more hydrophilic BAs 













































































Hydrophobic BAs Decreased Hepatocyte Viability via Cleaved-Caspase-3 
Mediated Apoptosis.  
(A&B) Cells were stained with propidium iodide (1 µg/mL) and Hoechst 33342 (1 
µg/mL) followed by fluorescence microscopy. Both apoptotic (condensed and 
fragmented nuclei) and PI positive cells were considered dead cells, and the 
percentage of viable cells was calculated. More than 300 cells were counted from 
each experiment and data are means± SEM from 3 independent experiments. A is 
dose-response viability assay, and B is time-dependent viability assay. (C) Primary 
hepatocytes were treated with different concentrations of CA and CDCA for 6 h. 
Whole cell lysates were subjected to immunoblot analysis for caspase-3. * p<0.05 vs 
control. # p<0.05 vs 6 hours treatment.  
 
 
Figure 3.3 Cont’d 
 65 
BAs Increased p62 and LC3-II Proteins in Primary Cultured Mouse Hepatocytes 
Since hepatic BA levels were elevated in FXR KO mice (Sinal, Tohkin et al. 
2000; Kim, Morimura et al. 2007), we determined whether BAs would directly modulate 
p62 and LC3-II levels.  Exposure of primary hepatocytes to TCA, CA and CDCA 
increased p62 and LC3-II protein levels in a time-dependent manner (Figure 3.4A). 
Moreover, TCA, CA, CDCA and DCA, but not UDCA exposure increased p62 and LC3-
II protein expressions in a dose-dependent manner (Figure 3.4B). We have previously 
found that unlike the liver tissue, it was difficult to detect the LC3-I form in the primary 
cultured mouse hepatocytes. This either could be due to the high basal level of 
autophagy in primary cultured or the antibody that we used preferentially binding to 
LC3-II form (Ding, Ni et al. 2009; Ding, Li et al. 2010). Exposure of primary hepatocytes 
to CQ, which suppresses autophagy by increasing lysosomal pH, also increased p62 
and LC3-II protein levels in a time-dependent manner (Figure 3.4C). The increased cell 
death at 24 hours treatment might play a role in the changes of the levels of the proteins 
that we assessed. Indeed, BAs treatment increased the protein levels of p62, which is 
consistent with the 6 hours treatment.  In contrast to the results after 6 hours treatment, 
CDCA actually decreased LC3-II levels after 24 hours treatment likely due to the 
increased cell death (Figure 3.4D). Consistent with the immunoblotting analysis, BA- 
and CQ-treated hepatocytes had increased number and size of p62 dots (Figure 3.4E). 
BA treatment did not increase mRNA levels of Map1lc3b or Sqstm1/p62, but both CA 
and CDCA increased the mRNA level of Shp, a well-known FXR target gene that is 
induced by BAs (Figure 3.4F). CQ treatment slightly increased the expression of 
Map1lc3b and Sqstm1/p62 but decreased the expression of Shp (Figure 3.4F). These 
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results indicate that BA-induced p62 and LC3-II protein accumulations are due to post-
translational regulation but not due to regulation of gene transcription in primary mouse 
hepatocytes.  
No Increased Autophagic Flux in BA-treated Primary Mouse Hepatocytes  
 We next performed autophagic flux assays in BA-treated hepatocytes. Primary 
hepatocytes were exposed to BAs in the presence or absence of CQ for 6 h.  As can be 
seen, LC3-II levels were increased in BA-treated cells except for UDCA and were 
further increased in the presence of CQ, but the co-treatment of hydrophobic BAs with 
CQ had almost the same LC3-II levels as treatment with CQ alone (Figure 3.5A). 
Moreover, the co-treatment of UDCA with CQ had more LC3-II level than treatment with 
CQ alone, which suggests that UDCA induced autophagic flux. Furthermore, the 
number of GFP-LC3 puncta increased in BA-treated cells, but the number of GFP-LC3 
puncta was not further increased in cells co-treated with BAs and CQ compared to cells 
that were treated with CQ alone (Figure 3.5B and 3.5C). To further determine whether 
BAs-induced impaired autophagic flux would require FXR, we treated primary cultured 
FXR-/- hepatocytes with BAs in the presence of absence of CQ for 6 h. Similar to the 
results that we observed in WT hepatocytes, both CA and CDCA increased p62 protein 
level and did not further increase the LC3-II level in the presence of CQ compared to 
the CQ alone treatment (Figure 3.5D). These results indicate that more hydrophobic 
BAs did not increase autophagic flux in both WT and FXR-/- hepatocytes. In contrast, 
hydrophilic BA, UDCA appeared to induce autophagy flux, which suggests that UDCA 
may be protective due to the induction of autophagy. The lack of increased autophagic 
flux, together with increased p62 levels by BAs, suggests that hydrophobic BAs may 
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Figure 3.4 Cont’d 
BAs increased p62 and LC3-II protein levels in hepatocytes in a time- and dose-
dependent manner. 
Primary hepatocytes were treated with CA, CDCA, or TCA for 0, 2, 4, 6 and 8 h (A) 
or (B) with different concentrations of BAs for 6 h. Whole cell lysates were subjected 
to immunoblot analysis. Densitometry analysis data are presented as a ratio of 
control (n=3-4). (C) Primary mouse hepatocytes were treated with 100 µM of CA, 
CDCA, TCA and CQ (20 µM) for 24 hrs. Total cell lysate were subjected to 
immunoblot analysis, and densitometry analysis was performed as described in (A) 
(n=3). (D) Primary hepatocytes were treated with CQ for various time points and total 
cell lysates were subjected to immunoblot analysis, and densitometry analysis was 
performed as described in (A) (n=3). (E) Hepatocytes were treated with 100 µM of 
TCA, CA or CDCA for 6 h and immunostained for p62 followed by fluorescence 
microscopy. Representative images are shown. The number of p62 puncta per cell 
was quantified (>20 cells were counted in each experiment from at least 3 
independent experiments). (F) Primary hepatocytes were treated as in (E) and qRT-
PCR was performed. The gene expression levels were normalized to β-actin and 




















































UDCA but not more hydrophobic BAs increased autophagic flux in 
hepatocytes.  
(A) Primary hepatocytes were treated with 100 µM of UDCA, TCA, CA, CDCA, or 
DCA with or without CQ (20 µM) for 6 h. Total cell lysates were subjected to 
immunoblot analysis followed by densitometry analysis.  Digital data were presented 
as a ratio of control (n=4-8). (B) Primary hepatocytes were infected with adenoviral 
GFP-LC3 (100 viral particles per cell) overnight and treated with as in (A) followed by 
fluorescence microscopy. Representative GFP-LC3 images are shown. (C) The 
number of GFP-LC3 dots per cell was determined (>20 cells were counted in each 
experiment from at least 3 independent experiments). (D) Primary FXR−/− 
hepatocytes were treated with 100 µM of CA or CDCA, with or without CQ (20 µM) 
for 6 h. Total cell lysates were subjected to immunoblot analysis followed by 
densitometry analysis. Data were presented as a ratio of control (n = 3). 
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BAs did not Affect Lysosome or Proteasome Function in Hepatocytes 
Since BAs increased LC3-II and p62 levels in hepatocytes, a phenotype typically 
induced by the lysosomal inhibitor CQ, although the effects induced by BAs were less 
potent compared to CQ. We next determined the effects of BAs on lysosomal function. 
DQ-BSA is BSA that is heavily labeled with a BODIPY dye that it self-quenches. Once it 
enters lysosomal compartments, DQ-BSA is cleaved by lysosomal proteases, which 
causes release of a single, dye-labeled fluorescent peptide. Thus, the fluorescence 
intensity of DQ-BSA can be used to reflect lysosomal function (Klionsky, Abdalla et al. 
2012). We found BAs did not alter the fluorescence intensity released from DQ-BSA 
compared to control cells, but CQ treatment significantly decreased the fluorescence 
intensity (Figure 3.6A). Furthermore, cathepsin B activity was similar among cellular 
lysates prepared from BA-treated hepatocytes compared to lysates from control cells. 
As a positive control, lysates from E64D (a cysteine protease inhibitor)-treated cells had 
significantly decreased cathepsin B activity (Figure 3.6B). Because p62 protein levels 
may also be regulated by the proteasome, we next determined proteasome activity in 
BA-treated hepatocytes. Treatment with BAs did not alter the proteasome activity in 
hepatocytes but the addition of MG132 (a proteasome inhibitor) in the lysates 
decreased proteasome activity (Figure 3.6C). Collectively, these results suggest that 
unlike CQ, BAs do not directly disrupt lysosomal integrity or function. The accumulated 
p62 and LC3-II in BA-treated hepatocytes could be due to an impaired autophagic 










































































BAs did not directly affect lysosomal or proteasome functions. 
(A) Primary hepatocytes were pre-loaded with DQ-BSA (5 µg/ml) for 1 hr and then 
treated with BAs for 6 h. Fluorescence intensity from cleaved DQ-BSA was measured 
using total cell lysates. Hepatocytes were treated with BAs for 6 h, and total cell 
lysates were either incubated with z-RR-AMC for cathepsin B activity (B) or Suc-





























































































BAs impaired autophagosomal-lysosomal fusion.   
(A) Primary hepatocytes were infected with adenoviral GFP-LC3 (100 viral particles 
per cell) overnight and then treated with 100 µM of BAs, or 20 µM of CQ or EBSS for 
6 h. Cells were immunostained for LAMP-1 followed by confocal microscopy. 
Representative images are shown, and the lower panels are enlarged images from 
the boxed areas. Arrow heads: yellow dots (colocalization of GFP-LC3 puncta with 
LAMP-1) and arrows: GFP-LC3 puncta only. (B) Percentage of GFP-LC3 puncta 
colocalized with LAMP-1 (> 20 cells were counted in each experiment from at least 3 
independent experiments). (C) Primary hepatocytes were transfected with RFP-GFP-
LC3 plasmid for 24 h and then treated as in (A). Representative images are shown, 
and the lower panels are enlarged images from the boxed areas. Arrow heads: 
yellow dots (RFP-GFP-LC3 puncta) and arrows: RFP-LC3 puncta only. (D) Total 
RFP-LC3 and RFP-GFP-LC3 puncta were quantified and percentage of RFP-LC3 
only puncta was calculated (E) (> 20 cells were counted in each experiment from at 
least 3 independent experiments).  
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BAs Inhibited Autophagosomal-Lysosomal Fusion 
To determine whether BAs would affect the fusion of autophagosomes with 
lysosomes, we performed immunostaining for the lysosomal associated membrane 
protein 1 (LAMP-1), a lysosomal outer membrane protein, and quantified the 
colocalization of LAMP-1 with GFP-LC3 puncta after BA treatment. We found that cells 
treated with BAs decreased the colocalization of GFP-LC3 puncta with LAMP-1 
compared to control cells or cells cultured in Earle's Balanced Salt Solution (EBSS), 
which represent basal autophagy or starvation-induced autophagy (Figure 3.7A and 
3.7B), respectively. We also found that CQ treatment slightly increased the 
colocalization of GFP-LC3 puncta with LAMP-1 compared to untreated cells, suggesting 
that CQ did not affect the fusion of autophagosomes with lysosomes. To further confirm 
that BAs might impair the maturation of autophagosomes, we transfected hepatocytes 
with tandem RFP-GFP-LC3. In this assay, RFP fluorescence is more stable in acidic 
compartments, and GFP fluorescence is rapidly quenched, so mature autolysosomes 
will have red puncta. Blocking the fusion of an autophagosome with a lysosome or 
suppressing lysosomal degradation (i.e., increase lysosomal pH by CQ) increases the 
number of yellow puncta (Kimura, Noda et al. 2007; Ni, Bockus et al. 2011). Consistent 
with the GFP-LC3 and LAMP-1 colocalization results, the number of RFP only positive 
dots was significantly higher in control cells or amino acid-starved cells than in cells 
treated with BAs or CQ (Figure 3.7C-E). EM analysis also revealed that amino acid-
starved cells had more single membrane autolysosomes (Avd) with degraded contents 
(Figure 3.8A, arrows, and Figure 3.8B-C), whereas cells treated with BAs had more 
double membrane early autophagosomes (Avi) enclosing undegraded contents (Figure 
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3.8A, arrow heads, and Figure 3.8B-C).  Taken together, these data collectively 



























































































BAs induced accumulation of early autophagosomes. 
(A) Hepatocytes were treated with 100 µM of CA or CDCA or EBSS for 6 h. 
Representative EM images are shown. Right panels are enlarged images from the 
boxed areas. Arrow heads: early autophagosome (Avi) and arrows: autolysosome 
(Avd). M: mitochondria, N: nuclei. (B) Early autophagosomes (AVi) and late 
autophagosomes (AVd) were quantified and (C) AVi/AVd ratio is presented (>20 





BAs Decreased Levels of Rab7 and Its Targeting to Autophagosomes in 
Hepatocytes 
Rab7, a small GTPase protein, is important for regulating the fusion of 
autophagosomes with lysosomes (Jager, Bucci et al. 2004) (Chua, Gan et al. 2011). 
Therefore, we determined if BAs affected Rab7-mediated fusion of autophagosomes 
with lysosomes. Indeed, the Rab7 staining displayed a peri-nuclear pattern in non-
treated hepatocytes that is quite similar to the LAMP-1 staining, which is consistent with 
the notion that most Rab7 were localized on the late endosomal/lysosomal 
compartments. More importantly, we found that around 78% of GFP-LC3 puncta were 
colocalized with Rab7 positive compartments, which was decreased to approximately 
40-55% in hepatocytes treated with BAs (Figure 3.9A-B). In contrast, almost 90% of 
GFP-LC3 puncta were colocalized with Rab7 positive compartments in amino acid-
starved or CQ-treated hepatocytes. Furthermore, treatment with BAs also decreased 
the protein levels of Rab7, but not LAMP-1 or LAMP-2 (Figure 3.9C). These results 
suggest that BAs impair autophagosomal-lysosomal fusion likely due to decreased 
Rab7-mediated fusion events.  The possible cellular events induced by BAs that might 


























































BAs decreased the colocalization of GFP-LC3 with Rab7. 
(A) Primary hepatocytes were infected with adenovirus GFP-LC3 (100 viral particles 
per cell) overnight and then treated with BAs, CQ or EBSS for 6 h. Cells were then 
immunostained with Rab7 followed by confocal microscopy. Representative images 
are shown, and the lower panels are enlarged images from the boxed areas. Arrows: 
GFP-LC3 puncta only. (B) Percentage of GFP-LC3 colocalized with Rab7 was 
quantified (> 20 cells were counted in each experiment from at least three 
independent experiments). (C) Hepatocytes were treated with BAs for 6 h and total 
cell lysates were subjected to immunoblot analysis followed by densitometry analysis 



















BAs inhibit autophagic flux by suppressing Rab7-mediated autophagsomal-
lysosomal fusion in hepatocytes. 
A proposed model that BAs inhibit autophagic flux by suppressing Rab7-mediated 
autophagsomal-lysosomal fusion in hepatocytes. During autophagy induction, small 
pieces of isolation membranes grow to form double-membrane autophagosomes, a 
process that is regulated by Atg5-Atg12-Atg16 complex and LC3-PE conjugation 
(LC3-II). LC3 also directly interacts with autophagy substrate protein p62 and recruit 
p62 into autophagosomes. Autophagosomes then fuse with lysosomes to form 
autolysosomes, where LC3-II and p62 are degraded. This process is mediated by 
Rab7 and other fusion proteins on either autophagosomes or lysosomes. BAs 
activate FXR whereas activated FXR negatively regulates synthesis of hepatic BAs. 
BAs inhibit the fusion of autophagosomes with lysosomes in hepatocytes likely due to 
decreased expression of Rab7 and its targeting to autophagosomes, resulting in 
impaired autophagic flux. Impaired autophagic flux leads to the accumulation of LC3-




  BAs are known to exert hepatotoxicity and induce apoptosis by activating either 
the death receptor or extrinsic apoptosis pathways or necrosis (Jaeschke, Gores et al. 
2002; Woolbright and Jaeschke 2012; Woolbright, Antoine et al. 2013). However, the 
role of BAs in hepatic autophagy is not clear. A previous study showed that deoxycholic 
acid (DCA) treatment increased the number of GFP-LC3 puncta in primary rat 
hepatocytes (Zhang, Park et al. 2008). While the authors concluded that DCA induced 
autophagy in primary rat hepatocytes, their conclusion was questionable because no 
autophagic flux assay was conducted in their study. We also found that BAs increased 
LC3-II protein levels as well as the number of GFP-LC3 puncta, which are in agreement 
with this previous report. However, results from further autophagic flux assays clearly 
indicated that BAs inhibit autophagic flux in hepatocytes. 
How do BAs inhibit autophagic flux? Several mechanisms may lead to decreased 
autophagic flux, which include: (1) inhibition of the upstream induction of autophagy and 
autophagosome biogenesis; (2) direct inhibition of lysosomal function; or (3) inhibition of 
autophagosomal-lysosomal fusion.  We found that BA-treatment alone caused 
increased LC3-II levels and GFP-LC3 puncta; therefore, it is less likely that BAs inhibit 
upstream autophagosome biogenesis. Furthermore, our results also demonstrated that 
BAs did not affect cathepsin B or lysosomal proteolytic activity, suggesting that BAs 
may not directly impair lysosomal function. This is in agreement with a previous study 
reporting that TCA did not inhibit cathepsin activity or alter lysosomal pH in rat liver or in 
isolated rat hepatocytes (Larocca, Pellegrino et al. 1999).  Therefore it is likely that BAs 
might decrease autophagic flux by impairing autophagosomal-lysosomal fusion. Indeed, 
results from multiple different approaches including colocalization of GFP-LC3 with 
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LAMP-1, tandem RFP-GFP-LC3 assay and EM studies strongly support that BAs inhibit 
autophagosomal-lysosomal fusion.  We also found that BA treatment not only 
decreased Rab7 protein levels, but also decreased its targeting to GFP-LC3 positive 
compartments, which could eventually lead to decreased autophagosomal-lysosomal 
fusion.  Increased intracellular levels of Ca2+ by thapsigargin has been shown to block 
the recruitment of Rab7 to autophagosomes resulting in defects for autophagosomal-
lysosomal fusion (Ganley, Wong et al. 2011). Interestingly, BAs have also been shown 
to induce endoplasmic reticulum stress and elevated intracellular Ca2+ in rat 
hepatocytes (Tsuchiya, Tsuji et al. 2006). It would be interesting to determine the 
possible role of intracellular Ca2+ in BA-mediated inhibition of autophagosomal-
lysosomal fusion. 
What is the significance of the inhibition of hepatic autophagy by BAs? A large 
body of evidence suggests that FXR may act as a tumor suppressor against liver 
tumorigenesis.  FXR may act on multiple levels to suppress liver tumorigenesis via 
control of BA homeostasis, prevention of hepatocyte apoptosis, reduction of reactive 
oxygen species production, inhibition of hepatic inflammation, as well as activation of 
the expression of Shp (Wang, Fu et al. 2013). In contrast, an aberrant high level of BAs 
has been shown to act as a liver tumor promoter. Firstly, clinical studies reveal a close 
association between cholestatic liver diseases and liver cancer (Jansen 2007). 
Secondly, a CA-enriched diet strongly promotes diethylnitrosamine initiated liver 
tumorigenesis in mice (Yang, Huang et al. 2007). Thirdly, FXR KO mice, which have 
elevated levels of hepatic BAs, develop spontaneous liver tumors that are significantly 
reduced by feeding the mice with cholestyramine, a BA-sequestering resin (Yang, 
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Huang et al. 2007). However, it is not clear how BAs promote liver tumorigenesis, 
although it has been suggested that high levels of BAs might induce DNA damage to 
inactivate tumor suppressor genes, cell death, and the inflammatory response in the 
liver (Wang, Fu et al. 2013). Autophagy has been known to serve as a tumor 
suppressor. Beclin-1 heterozygous mice that have decreased expression of Beclin-1, a 
gene involved in the autophagy process, have increased spontaneous tumors in 
multiple tissues including liver (Qu, Yu et al. 2003). Furthermore, liver-specific Atg5 or 
Atg7 KO mice also have increased liver tumors but the tumor progression was 
significantly blunted in the Atg7/p62 double KO mice (Inami, Waguri et al. 2011; 
Takamura, Komatsu et al. 2011), supporting the notion that autophagy is a bona fide 
tumor suppressor and increased p62 levels could be one of the important factors 
responsible for the tumorigenesis associated with impaired-autophagy. We recently 
demonstrate that further deletion of Nrf2 completely abolished tumorigenesis in liver-
specific Atg5 KO mice, suggesting that Nrf2 is the major player downstream of p62 to 
promote liver tumorigenesis (Ni, Woolbright et al. 2014). It will be interesting to 
determine whether Nrf2 is activated by BAs or increased in FXR KO mouse livers in the 
future.  We previously found that FXR can directly bind to the Sqstm1/p62 gene as 
determined by chromatin immunoprecipitation (Williams, Thomas et al. 2012). However, 
when mice were treated with a synthetic FXR agonist, we found that the mRNA and 
protein expression levels of Sqstm1/p62 only increased in mouse ileum but not in liver. 
How FXR differentially regulate Sqstm1/p62 expression in different mouse tissues is still 
not clear. However, we found that p62 protein accumulated in FXR KO mouse liver, 
suggesting that other transcriptional factor (s) would be important in the regulating the 
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expression of Sqstm1/p62. Nevertheless, the findings that BAs inhibited autophagic flux 
in primary cultured mouse hepatocytes and in mouse liver in the present study suggest 
that decreased autophagy may be a novel mechanism that accounts for the liver 
tumorigenesis induced by BAs, and for the tumorigenesis observed in FXR KO mice. 
In conclusion, we demonstrated that BAs inhibit autophagic degradation in vitro 
and may also play a role in the impaired hepatic autophagy in FXR KO mice in vivo. We 
further demonstrated that BAs decreased the expression of Rab7 and targeting to the 
autophagosome resulting in decreased autophagosomal-lysosomal fusion. Autophagy 
deficiency has been shown to cause liver injury and promote liver tumorigenesis, and 
increased concentrations of BAs have been linked to spontaneous liver tumor 
development in FXR KO mice. Therefore, our results suggest a possible link between 
BAs and impaired autophagy in BA-induced hepatotoxicity and liver tumorigenesis. 
Modulating autophagy function could be a promising therapeutic approach for 













CHAPTER 4:  










4.1 Specific Aim 2 
The role of FXR, a master bile acid homeostasis regulator, in alcohol-induced liver injury 
is unknown. Increased bile acids have been shown to inhibit autophagy, and FXR KO 
mice have impaired hepatic autophagy. We previously showed that autophagy protects 
against ethanol-induced steatosis and liver injury. We also showed that activation of 
hepatic FoxO3a increased autophagy and protects against ethanol-induced steatosis 
and liver injury in mice. Therefore, I hypothesized that FXR may be required for 
ethanol-induced FoxO3a-mediated autophagy in mouse livers and deletion of FXR 








































Diagram of the Specific Aim 2.  
Aim 2a is to determine if FXR interacts with and promotes FoxO3a stabilization and 
translocation to the nucleus. Aim 2b is to examine if FXR regulates interaction of 
FoxO3a with its cofactors. Aim 2c is to investigate if FXR is involved with modulation 
of post-translational modifications of FoxO3a. FXR regulation of alcohol-induced 
FoxO3a activation is expected to be a protective mechanism against alcohol-induced 
liver injury and steatosis.  
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4.2 Aim 2a: To determine the interaction of FXR with FoxO3a after ethanol 
treatment.  
The objective of this aim is to determine if FXR is required for FoxO3a stabilization and 
translocation to the nucleus allowing FoxO3a to initiate cell protective gene expressions 
in response to ethanol exposure. I hypothesized that FXR is required for FoxO3a 
activation and translocation to nucleus to initiate transcription of FoxO3a target 
genes. This hypothesis is formed based on the preliminary data that showed the 
difference in the gene expression profiles between ethanol treated WT and FXR KO 
mouse livers. The data revealed that in ethanol treated FXR KO mouse livers that 
ethanol-induced increases in mRNA of FoxO3a target genes were abolished. The data 
suggest that FXR may be required for FoxO3a stabilization and translocation in 
response to acute ethanol exposure. However, the mechanism of how FXR regulates 
FoxO3a is not known.  
4.3 Aim 2b: To determine that FXR is required for the interaction of co-factors 
with FoxO3a. My long-term goal is to examine to what degree FXR is involved with 
modulating the interactions of known co-factors with FoxO3a and subsequently 
modifying the activation of FoxO3a. The objective of this aim is to investigate to what 
degree FXR regulates the interactions of the co-factors with FoxO3a using both in vivo 
and in vitro models. I hypothesized that FXR may be necessary for activation of 
FoxO3a by co-factors. My hypothesis was based on previous published data showing 
that FoxO3a interacts with several co-factors including PGC-1α and various nuclear 
receptors to either upregulate or downregulate gene transcription (van der Vos and 
Coffer 2008).  FXR also shares a couple of co-factors, PGC-1α and Sirt1, with FoxO3a 
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(Kemper 2011). Currently, it is not known if FXR regulates the interaction of FoxO3a 
with the activating co-factors.  
 
4.4 Aim 2c: To determine that FXR affects the post-translational modifications of 
FoxO3a and the nuclear stabilization of FoxO3a. My long-term goal is to identify 
what post-translational modifications of FoxO3a is regulated by FXR in response to 
ethanol exposure and how it regulates the localization of FoxO3a. The objective is to 
identify the post-translational modifications that are modified in response to ethanol in 
WT and FXR KO mice. I hypothesized that FXR KO mice livers have altered post-
translational modifications and cellular localization of FoxO3a in response to 
ethanol exposure compared to WT mouse livers.  My hypothesis was based on 
previously published data showing that FoxO3a activation and localization is regulated 
by a number of post-translational modifications including phosphorylation, acetylation, 
and ubiquitination.  FXR is an emerging key protein in regulation of many signaling 
pathways particularly in glucose and lipid metabolism in liver. Similiarly, FoxO3a has 
been also shown to be involved in glucose and lipid homeostasis. Sirt1 is a known co-
factor regulating both FoxO3a and FXR by acetylating both molecules. Moreover, the 
FXR- SHP pathway inhibits miRNA-34a to positively regulate hepatic Sirt1 levels (Lee, 
Padhye et al. 2010). Sirt1 deacetylates FoxO3a, which targets FoxO3a to Skp2-
mediated ubiquitination and degradation (Wang, Chan et al. 2012). Intriguingly, 
acetylation of FoxO3a also results in impaired DNA-binding function (Daitoku, Sakamaki 
et al. 2011).  It has been reported that chronic ethanol administration down regulates 
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Sirt1 in rat and mouse livers (Lieber, Leo et al. 2008; You, Liang et al. 2008). However 


































FARNESOID X RECEPTOR REGULATES FORKHEAD BOX O3A ACTIVATION IN 










The portions of this section are reproduced from following publication with 
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Farnesoid X Receptor Regulates Forkhead Box O3a Activaiton in Ethanol-




Alcohol is widely consumed in the United States and worldwide, and can be 
beneficial in moderation. Excessive alcohol consumption and abuse may result in 
alcoholic liver disease (ALD), a major contributor of liver diseases and deaths (Ding, 
Manley et al. 2011; Gao and Bataller 2011). Pathogenesis of ALD initiates with simple 
steatosis in the majority of patients and progresses to more severe pathologies 
including fibrosis, alcoholic hepatitis, and cirrhosis in a fraction of the patients. In 
exceptional cases, ALD may progress to hepatocellular carcinoma (Gao and Bataller 
2011). Binge drinking is a form of alcohol abuse defined by consuming more than 5 
drinks (males) or 4 drinks (females) in a two-hour period (Wechsler and Austin 1998). 
About one out of three adults displays high-risk drinking patterns including binge 
drinking, but less attention has been given to acute alcohol liver injury despite the fact 
that binge drinking is more common than chronic alcohol abuse (Ding, Manley et al. 
2011). At the physiological level, binge drinking induces glycogen depletion, acidosis, 
and hypoglycemia (Zakhari and Li 2007). At the cellular level, binge drinking results in 
mitochondria damage, ablated insulin signaling, steatosis, and free radical generation 
(Bailey and Cunningham 2002; Carmiel-Haggai, Cederbaum et al. 2003; Lieber 2004; 
He, de la Monte et al. 2007; Lu and Cederbaum 2008). Paradoxically, binge drinking 
induces autophagy as a cellular protective mechanism to selectively degrade damaged 
mitochondria (mitophagy) and lipid droplets (lipophagy), whereas suppression of 
autophagy by pharmacological inhibitors or small interfering RNAs exacerbates alcohol-
induced hepatotoxicity and steatosis (Ding, Li et al. 2010; Ding, Li et al. 2011).  
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 Autophagy is a cellular lysosomal degradation pathway responsible for 
degradation of cellular protein and damaged organelles to promote cell survival 
(Mizushima, Yoshimori et al. 2010). The autophagy process is characterized by 
formation of circular double membrane structures containing cargo known as 
autophagosomes. Autophagosomes then fuse with lysosomes to form autolysosomes to 
complete the degradation of the autophagic cargo (Mizushima, Yoshimori et al. 2010). 
More than 30 Atg genes have been identified as participants in autophagy in yeast, and 
most of them have mammalian homologues (Klionsky and Emr 2000).  Among them, 
two ubiquitin conjugation systems include Atg7 (E1-like protein), Atg3 (E2-like) and 
Atg5-Atg12-Atg16 complex (E3 ligase) play an essential role to mediate the conjugation 
of phosphatidylethanolamine (PE) to microtubule associated protein light chain 3 (LC3) 
(Kabeya, Mizushima et al. 2000; Ohsumi 2001). This conjugated form of LC3 is known 
as LC3-II, and the unconjugated form of LC3 is referred as LC3-I (Kamada, Sekito et al. 
2004). LC3-II is targeted to the autophagosomal membrane, where the inner membrane 
LC3-II is degraded and the outer membrane LC3-II is de-conjugated and recycled 
(Kirisako, Ichimura et al. 2000). Induction of autophagy or inhibition of autophagy 
degradation causes LC3-II accumulation; therefore, LC3-II is used as a marker to 
monitor autophagic flux (Klionsky, Abdalla et al. 2012).  Sequestome-1 (Sqstm1)/p62 is 
another specific autophagy substrate that also can be used to monitor autophagic flux, 
and is accumulated in autophagy deficient cells or mouse liver (Komatsu, Waguri et al. 
2007; Kirkin, Lamark et al. 2009; Ni, Boggess et al. 2012).   
  FoxO3a is a member of the FoxO transcription factor family and regulates the 
transcription of genes involved with apoptosis, oxidative stress, cell-cycle transition and 
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DNA repair (Huang and Tindall 2007; Tzivion, Dobson et al. 2011).  FoxO3a also 
regulates the autophagy related gene expression in skeletal muscles (Mammucari, 
Milan et al. 2007; Zhao, Brault et al. 2007), cardiomyocytes (Sengupta, Molkentin et al. 
2011), and liver (Ni, Du et al. 2013). Multiple post-translational modifications including 
phosphorylation, ubiquitination, acetylation, and methylation regulate the FoxO3a 
cellular localization and DNA-binding affinity (Huang and Tindall 2007; Tzivion, Dobson 
et al. 2011). Akt is the canonical regulator of FoxO3a by phosphorylating FoxO3a on 
serine 253 and sequestering FoxO3a in the cytosol, which renders FoxO3a unable to 
bind DNA and induce gene transcription (Tzivion, Dobson et al. 2011). We have 
recently demonstrated that acute ethanol treatment inhibits Akt-mediated 
phosphorylation of FoxO3 resulting in nuclear FoxO3a retention and increased 
transcription of autophagy genes in mouse livers and primary mouse and human 
hepatocytes (Ni, Du et al. 2013).  
 Farnesoid X receptor (FXR), the master regulator of bile acids homeostasis, is a 
member of the nuclear hormone receptor superfamily and is highly expressed in liver 
and intestines (Forman, Goode et al. 1995; Sinal, Tohkin et al. 2000; Kim, Morimura et 
al. 2007). Bile acids are identified as the endogenous ligands for FXR, and bile acid-
mediated FXR activation increases the expression of SHP, which serves as a negative 
regulator of bile acid synthesis. As a result, FXR knockout (KO) mice display elevated 
hepatic bile acid level due to the lack of SHP-mediated inhibition on bile acid synthesis 
(Sinal, Tohkin et al. 2000; Kim, Morimura et al. 2007). We recently demonstrated that 
FXR KO mice display impaired hepatic autophagy due to increased hepatic bile acid 
levels. Furthermore, bile acids suppress autophagosomal-lysosomal fusion (Manley, Ni 
 100 
et al. 2014). Recent studies showed that activation of FXR protected against ethanol-
induced hepatotoxicity and steatosis (Xie, Zhong et al. 2013; Livero, Stolf et al. 2014). 
However, whether FXR would play a role in ethanol-induced autophagy is not known.  
In the present study, we found that FXR was critical for protecting against acute 
ethanol-induced hepatotoxicity and steatosis by indirectly promoting ethanol-induced 
nuclear FoxO3 retention and activation.  In response to acute ethanol treatment, there 
was an increased Akt activation resulting in decreased nuclear FoxO3a retention and 
FoxO3a-mediated expression of autophagy related genes in FXR KO mice. Acute 












5.2 MATERIALS AND METHODS 
Reagents. The following antibodies were used: Atg5 (PM050) from MBL International 
(Woburn, MA), p62 (H00008878-M01) and PGC-1α (PAB-12061) from Abnova (Taipei, 
Taiwan), Beclin-1 (sc11427), FXR (sc13063), CHOP/GADD152 (sc793), HA (sc805), 
mitofusin-1 (sc50330), and Parkin (sc32282) from Santa Cruz Biotechnology (Santa 
Cruz, CA), beta-actin (a5541), Bip/GRP78 (G9043), Flag (F3165), and mitofusin-2 
(M6444) from Sigma (St. Louis, MO), acetylated lysine (9441S) serine 473 
phosphorylated Akt (4058), Akt (9272), serine 9 phosphorylated GSK3β (5558S), 
GSK3β (5676S), serine 253 phosphorylated FoxO3a, FoxO3a (2497), GAPDH (2118), 
Lamin A/C (2032), and Sirt1 (2028) from Cell Signaling Technology (Beverly, MA), and 
CYP2E1 (ab28146) from Abcam (Cambridge, MA). The rabbit polyclonal anti-LC3B 
antibody was described previously (Ding, Ni et al. 2009). The secondary antibodies 
used for immunoblotting analysis were HRP-conjugated goat anti-mouse (115-035-062), 
rabbit (111-035-045), and rat (111-035-143) and a Dylight 549 conjugated goat anti-
rabbit (111-505-144) antibody from Jackson ImmunoResearch (West Grove, PA) or an 
HRP-conjugated goat anti-rabbit antibody (31460) from Thermo Fisher Scientific 
(Waltham, MA). Ethanol was from Pharmaco (Brookfield, CT). All other chemicals were 
from Sigma-Aldrich, (St. Louis, MO), Thermo Fisher Scientific (Waltham, MA), 
Invitrogen (Carlsbad, CA), or EMD Millipore (Billerica, MA). 
Animal Experiments. Wild type C57BL/6 and FXR -/- C57BL/6 mice were purchased 
from Jackson Laboratory (Bar Harbor, ME). 2-4 months age matched male wild type 
and FXR -/- mice were used in this study. All mice were provided with humane care 
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according to the NIH guidelines, and the Institutional Animal Care and Use Committee 
at the University of Kansas Medical Center approved all procedures.  
Mouse Ethanol Binge Treatment. The ethanol binge model was modified from the 
model Carson and Pruett established, which has been shown to closely mimic human 
binge ethanol consumption including blood alcohol levels and behavioral effects 
(Carson and Pruett 1996). The mice were fasted for 6 hours, and then administered with 
33% (v/v) ethanol at a cumulative dose of 4.5 g/kg body weight by four equally divided 
gavage in 15 minutes intervals. Control mice received same volume of double-distilled 
water. For WAY-363450 treatment, the mice were administered 30 mg/kg body weight 
WAY-362450 after 6 hours fast and prior to ethanol treatment. Control and ethanol-only 
treated mice received same volume of PEG400:Tween20 solution (80:20 ratio). Mice 
were sacrificed 16 hours later after the treatment, and serum and liver samples were 
harvested. Serum alanine aminotransferase (ALT) levels and H&E staining were used 
to assess ethanol-induced liver injury. Total liver lysates were obtained by using radio-
immunoprecipitation assay buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl (lauryl) sulfate). 
Cell Culture and Transfection. Human embryonic kidney 293A cells were cultured in 
DMEM medium with FBS and L-glutamate and transiently transfected with HA tagged 
FoxO3, Flag tagged FXR, HA or Flag plasmid constructs using TurboFect Transfection 
reagent (Thermo Fisher Scientific) for 24 hours.  Total cell lysates then were extracted 
using HA cell lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM EDTA pH 7.5, 1 
mM EGTA pH 7.5, 1% Triton X-100, protease inhibitors).  
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Hepatic Triglyceride Analysis. Frozen liver tissues (50-100 mg) were grounded to fine 
powder using mortar and pestle. The powdered tissue was incubated in 1 ml of 
chloroform/methanol (2:1) mix with vigorous shaking for 1 hour at room temperature. 
200 µl of double-distilled water was added, and the mixture was centrifuged for 5 
minutes at 3000 x g at 4°C. The aqueous upper phase layer then was collected and air-
dried at room temperature. The dried pellet was dissolved in tert-butanol and Triton X-
114/methanol (2:1) solution. Hepatic triglyceride analysis was performed with a 
colormetric assay kit according to manufacturer’s instructions (Pointe Scientific, Ann 
Arbor, MI). 
Immunoblot Assay. Equal amount of nuclear fraction (15 µg), cytosol fraction (30 µg), 
or total liver lysates (50 µg) were separated by SDS-PAGE gel and transferred to PVDF 
membranes. The membranes were immunoblotted with primary antibodies followed by 
HRP-conjugated secondary antibodies. The membranes then were developed with 
either Pierce Supersignal West Pico chemiluminescent substrate (Thermo Fisher 
Scientific, Rockford, IL) or Millipore Immobilon Western chemiluminescent HRP 
substrate (Billerica, MA). Densitometry was performed using ImageJ software and 
further normalized using beta-actin or GAPDH, and expressed as means + SEM. 
qPCR. RNA was isolated from liver tissues using TRIzol (Life Technologies, Waltham, 
MA) and reverse transcribed into cDNA by RevertAid reverse transcriptase (Thermo 
Fisher Scientific, Waltham, MA). Real-time PCR was performed on a Bio-Rad 
CFX384™ real-time PCR detection system using iTaq™ Universal SYBR® Green 
Supermix (Bio-Rad). The following genes were probed with quantitative PCR using β-
actin gene as loading control: Atg5, Becn-1, Map1lc3b, MnSOD, p21, FoxO3a, Sqstm-1, 
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and Shp. Primer sequences were as follows: β-actin, 5’-TGTTACCAACTGGGACGACA-
3’ and 5’-GGGGTGTTGAAGGTCTCAAA-3’; Atg5, 5’-GACCACAAGCAGCTCTGGAT-3’ 
and 5’-GGTTTCCAGCATTGGCTCTA-3’; Becn-1 (Atg6), 5’-
TGATCCAGGAGCTGGAAGAT-3’ and 5’-CAAGCGACCCAGTCTGAAAT-3’; FoxO3a, 
5’-AGCCGTGTACTGTGGAGCTT-3’ and 5’-TCTTGGCGGTATATGGGAAG-3’; 
Map1lc3, 5’-CCGAGAAGACCTTCAAGCAG-3’ and 5’-ACACTTCGGAGATGGGAGTG-
3’; MnSod, 5’-GGCCAAGGGAGATGTTACAA-3’ and 5’-
AGACACGGCTGTCAGCTTCT-3’; p21, 5’-CGGTGGAACTTTGACTTCGT-3’ and 5’-
CAGGGCAGAGGAAGTACTGG-3’; Sqstm1/p62, 5’-AGAATGTGGGGGAGAGTGTG-3’ 
and 5’-TCGTCTCCTCCTGAGCAGTT-3’; and Shp, 5’-CTGCAGGTCGTCCGACTATT-3’ 
and 5’-ACCTCGAAGGTCACAGCATC-3’.  
Immunoprecipitation. Total cell lysates (200 µg) or total liver lysates (500 µg) were 
incubated with a FoxO3a antibody (sc11351, Santa Cruz) overnight at 4°C rotating and 
pulled down with protein A/G agarose beads (sc2003, Santa Cruz) or EZview™ Red 
ANTI-FLAG® M2 Affinity Gel (F2425, Sigma). Immunoblot analysis was performed with 
immunoprecipitated and input proteins.  
 
Chromatin Immunoprecipitation. Fresh liver sections were minced or frozen liver 
sections were homogenized and cross-linked with 1% formaldehyde in PBS. Following 
incubation, the livers were quenched with 250 mM glycine. Crude nuclear extracts were 
obtained using hypotonic buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 3 mM MgCl2, 
0.5% NP-40) and nuclear lysis buffer (1%SDS, 5 mM EDTA, 50 mM Tris-HCl pH 8.0). 
The chromatin extracts were then sheared using Active Motif Q800R sonicator to 200-
500 base pair fragments.  Chromatin proteins (600 µg) were immunoprecipitated with a 
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FoxO3a antibody (sc11351X) from Santa Cruz Biotechnology (Santa Cruz, CA) binded 
with Dynabead Protein A (10001D) from Invitrogen/Dynal (Oslo, Norway). DNA was 
then extracted from immunoprecipitated and input chromatin using GeneJet PCR 
Purification Kit (K0701) from Thermo Scientific (Waltham, MA). qPCR was performed 
and three FoxO3a binding sites in the Map1LC3b promoter site were probed. Primer 
sequences were as follows: 1379 to 1608 base pairs upstream, 5’-
CATGCCTTGGGACACCAGAT-3’ and 5’-ACCTTCTTCAAGTGCTGTTTGT-3’; 3397 to 
3595 base pairs upstream, 5’-TTTGACCAAACAGGGTTTCC-3’ and 5’-
CCCTCCAGGTGTTTGTGATAA-3’; and 4673 to 4801 base pairs upstream, 5’-
CCTCAGCTGGCTAAGAGCAT-3’ and 5’-CCC AAG GAT CTC AAC CAA AC-3’. The 
primer sequences were obtained from a previous report (Zhao, Brault et al. 2007).  
Fluorescence and Electron Microscopy. Liver sections were fixed with 4% 
paraformaldehyde then incubated in 20% sucrose in PBS and embedded in optimal 
cutting temperature (OCT) solution at -20°C. Liver cyrosections were immunostained 
with FoxO3a antibody followed by Dylight 549 conjugated secondary antibody and 
Hoechst 33342 staining.  The images of sections were acquired under a Nikon Eclipse 200 
fluorescence microscope with MetaMorph software. For electron microscopy (EM), liver 
sections were fixed with 2.5% glutaraldehyde in 0.1 mol/L sodium cacodylate buffer (pH 
7.4), followed by 1% OsO4. After dehydration, thin sections were cut and stained with 
uranyl acetate and lead citrate. Digital images were obtained using a JEM 1016CX 
electron microscope.  
Nuclear Fractionation. Mouse liver cytosol and nuclear proteins were extracted using 
NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) 
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according to manufacturer’s instructions. In brief, 50-100 mg of liver was homogenized 
in cytoplasmic extraction reagent I, followed by addition of cytoplasmic extraction 
reagent II, and centrifuged. The supernatant was collected as cytoplasmic fraction, and 
the insoluble pellet was suspended in nuclear extraction reagent and centrifuged. The 
resulting supernatant contains nuclear fraction.  
Statistic Analysis. All experimental data were expressed as means ± SE and 
subjected to Student t-test or one-way analysis of variance with Holm-Sidak post hoc 
test or one-way analysis of variance on ranks with Dunn post hoc test where 













Acute ethanol treatment exacerbated liver injury and steatosis in FXR KO mice 
compared to WT mice.  
Acute ethanol treatment increased serum alanine aminotransferase (ALT) levels 
and hepatic triglyceride levels in wild type (WT) mice, which is consistent with our 
previous report (Ding, Li et al. 2010). Compared to WT mice, acute ethanol-treated FXR 
KO mice had higher serum ALT and hepatic triglyceride levels, suggesting ethanol 
treatment exacerbated liver injury and steatosis in FXR KO mice (Figure 5.1A & B). 
Notably, control FXR KO mice already had a mild increase of serum ALT, which is 
consistent with previous reports suggesting the lack of FXR causes mild liver injury 
(Yang, Huang et al. 2007)(Figure 5.1A). However, there was no difference in hepatic 
triglycerides level between age matched WT and FXR KO control mice (Figure 5.1B). 
Moreover, there was no difference in the liver weight/body weight ratio between control 
and ethanol-treated WT and FXR KO mice (Figure 5.1C). Hematoxylin and eosin 
staining revealed that ethanol induced mild hepatic steatosis in WT mice, which was 
further exacerbated in FXR KO mice (Figure 5.2). In line with these findings, oil red o 
staining for lipids showed that ethanol treatment increased oil red o staining in WT 
mouse livers compared to control mice. However, oil red o staining was much more 
severe in ethanol-treated FXR KO mouse livers compared to ethanol-treated WT mouse 
livers, suggesting that lack of FXR exacerbates ethanol-induced hepatic steatosis 
(Figure 5.3). Furthermore, EM analysis also revealed that ethanol treatment increased 
the number of lipid droplets in WT mouse livers. The number of lipid droplets was 
further increased in ethanol-treated FXR KO mouse livers compared to WT mouse 
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livers (Figure 5.4A & B). Taken together, these data indicate that FXR deficiency 














































































FXR KO mice exhibited increased ethanol-induced liver injury and steatosis. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Serum alanine aminotransferase (ALT) (A) and hepatic 
triglycerides (TG) (B) were measured (n=4-10). Liver/body weight ratio was 
calculated (C) (n=4-10). *: p<0.05  



















H & E staining showed that FXR KO mice exhibited increased ethanol-induced 
steatosis. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Representative H&E stain images are shown. Right images are 




















Oil Red O staining revealed FXR KO mice exhibited increased ethanol-induced 
steatosis. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
































  FXR KO mice exhibited increased ethanol-induced lipid droplet formation. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Representative EM images are shown in (A) and lipid droplets 
(LD) are quantified from at least 24 different liver section (B). *: p<0.05  
Figure 5.4 Cont’d 
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Acute ethanol treatment induced endoplasmic reticulum stress.  
 Chronic alcohol consumption has been shown to induce endoplasmic reticulum 
(ER) stress response in mouse livers (Ji 2014). In agreement with previous findings, the 
EM analysis showed ER dilation, a sign of ER stress in acute ethanol-treated WT 
mouse livers (Figure 5.5A).  The dilated ER seemed to be more severe in ethanol-
treated FXR KO mouse livers than that of WT mice. Acute ethanol treatment did not 
increase binding immunoglobulin protein (Bip), a marker of ER stress. However, 
CCAAT-enhancer-binding-protein homologous protein (CHOP), another ER stress 
marker was increased in both WT and FXR KO mouse livers after acute ethanol 
treatment (Figure 5.5B). These results suggest that ethanol may induce ER stress in 
the mouse livers, but the whether FXR KO mouse livers had more severe ER stress 
than that of WT mice need to be further studied. More ER stress markers such as 
eukaryotic initiation factor 2-alpha (eIF2-α) phosphorylation, Atg4 and activating 
transcription factor 6 (ATF6) as well as the splicing of x-box binding protein 1 (XBP1) 





























Ethanol induced ER stress response.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Representative EM images are shown in (A). M- Mitochondria. 
ER- endoplasmic reticulum. Total liver lysates were subjected to immunoblot analysis 
for ER stress proteins, Bip and CHOP/GADD153 (B). Densitometry analysis data are 





Impaired autophagy in acute ethanol-treated FXR KO mouse livers.  
 We previously demonstrated that FXR KO mice have impaired hepatic 
autophagy (Manley, Ni et al. 2014).  In accordance with previous findings, we showed 
that control FXR KO mice had higher basal LC3-II and p62 protein levels compared to 
WT mice. Ethanol treatment slightly increased LC3-II protein levels in WT but not FXR 
KO mouse livers (Figure 5.6A). However, ethanol treatment increased p62 protein 
levels in WT mouse livers, which was further increased in FXR KO mouse livers  
(Figure 5.6A). Ethanol treatment also increased CYP2E1 protein levels in both WT and 
FXR KO mouse livers (Figure 5.6B), consistent with previous reports (Wu and 
Cederbaum 1993; Caro and Cederbaum 2004). Ethanol treatment increased the mRNA 
levels of p62 in WT mouse livers but not in FXR KO mouse livers (Figure 5.6C), 
suggesting that ethanol treatment-increased p62 protein levels could be mediated at the 
transcriptional level in WT mice but not in FXR KO mice. These data suggest that 
impaired hepatic autophagy in FXR KO mice results in increased ethanol-induced p62 
protein accumulation. EM analysis revealed that ethanol treatment increased the 
number of autolysosomes in WT mouse livers although did not reach the statistical 
significance. Consistent with our previous report (Manley, Ni et al. 2014), control FXR 
KO mice already had increased number of autophagosomes and autolysosomes likely 
due to impaired fusion of autophagosomes with lysosomes.  Treatment with acute 
ethanol further increased the number of autophagosomes and autolysosomes (Figure 
5.7A & B). Furthermore, FXR KO mouse livers showed increased percentage of 
autophagosomes in comparison to WT mouse livers, which suggests that fusion of 
autophagosomes with lysosomes may be impaired (Figure 5.7C). These results 
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indicate that there was impaired autophagy in FXR KO mouse livers, which might 

































































Autophagy was impaired in acute ethanol-treated FXR KO mice.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Total liver lysates were subjected to immunoblot analysis for 
autophagy-related proteins, p62 and LC3 (A) and ethanol-metabolizing enzyme, 
CYP2E1 (b). Densitometry analysis data are presented as a ratio of control (n = 3–4). 
Hepatic mRNA was isolated and qRT-PCR was performed for Sqstm1 (C). The gene 
expression levels were normalized to β-actin and shown as fold increase over wild 



























































EM Analysis showed that autophagy was impaired in acute ethanol-treated FXR 
KO mouse livers.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Representative EM images are shown in (A). Right image is the 
enlarged image from the box area. White arrows: early autophagosomes (Avi) and 
yellow arrows: autolysosomes (Avd) (A). Autophagosomes (Avi) and autolysosomes 
(Avd) were quantified (B) (<24 different liver sections). Ratio of Avi over total AV also 
was calculated (C). *: p<0.05 
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Lack of FXR impaired acute ethanol-induced FoxO3a activation.   
We previously reported that acute ethanol treatment induces FoxO3a-mediated 
hepatic expression of autophagy related genes (Ni, Du et al. 2013). Consistent with our 
previous report, ethanol treatment increased the mRNA levels of Atg5, Becn-1 and 
Map1lc3b in WT mouse livers (Figure 5.8A). In contrast, ethanol treatment did not 
cause such an increase, and actually showed a slight decrease of hepatic expression of 
these autophagy related genes in FXR KO mice. In addition to autophagy related 
genes, ethanol treatment also increased expression of MnSod, p21 and FoxO3a, which 
are known FoxO3a target genes in WT but not in FXR KO mouse livers (Figure 5.8B). 
Shp (small heterodimer partner) is a well-known target gene of FXR, and ethanol 
treatment had no effect on the expression of hepatic Shp mRNA level in WT mice, 
suggesting that acute ethanol treatment may not activate FXR. In contrast, FXR KO 
mice had dramatically decreased expression of hepatic Shp, which was further 
decreased with ethanol treatment (Figure 5.8C). The immunoblotting analysis showed 
that ethanol treatment did not increase Atg5 or Beclin-1 protein levels (Figure 5.9). It is 
possible that these proteins could be used for the induction of autophagosome 
formation at that particular time point.  A detail time-course study for the autophagy-
regulating proteins after ethanol treatment may be needed in the future. In conclusion, 
these results suggest that lack of FXR impairs ethanol-induced FoxO3a activation in 





























































Ethanol-induced FoxO3a-mediated transcription of autophagy and FoxO3a 
target genes was inhibited in FXR KO mouse livers.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Hepatic mRNA was isolated and qRT-PCR was performed for 
autophagy genes, Atg5, Becn-1, and Map1lc3B (A) and FoxO3a target genes, 
MnSOD, p21, and FoxO3a (B). qRT-PCR was also performed for FXR target gene, 
Shp (c). The gene expression levels were normalized to β-actin and shown as fold 






























Ethanol did not increase Atg5 or Beclin-1 protein levels.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Total liver lysates were subjected to immunoblot analysis for 
autophagy-related proteins, Atg5 and Beclin-1. Densitometry analysis data are 





No direct interaction between FoxO3a and FXR both in vitro and in vivo.  
To determine whether FXR would directly interact with FoxO3a, we transiently 
transfected with HA-tagged FoxO3a, Flag-tagged FXR, or both in human embryonic 
kidney (HEK) 293A cells. We found that there was a weak interaction between Flag-
FoxO3a and HA-FXR. However, Flag tag only also showed similar weak interaction with 
HA-FXR, suggesting that the interaction between Flag-FoxO3a and HA-FXR is not 
specific. Immunoblotting analysis of the total lysate revealed that the transfection was 
efficient in HEK293 cells (Figure 5.10A). We further found that FoxO3a was present in 
both nuclear and cytosolic fractions, whereas FXR was dominantly expressed in nuclear 
fraction, suggesting that the lack of interaction between FXR and FoxO3a was not due 
to the alterations of cellular localization as a result of the overexpression of these two 
proteins (Figure 5.10B). To determine whether endogenous FXR in mouse livers would 
interact with endogenous FoxO3a, and whether this interaction would be altered by 
ethanol treatment, immunoprecipitation was performed using endogenous liver proteins 
from mouse livers with or without the ethanol treatment.  Similar to the results from the 
overexpression of FoxO3a and FXR in HEK293 experiment, no interaction between 
FoxO3a and FXR was found in either control or ethanol-treated mouse livers (Figure 
5.10C). These results suggest that FXR may not directly interact with FoxO3a in 










































FXR and FoxO3a did not interact in vitro or in vivo.  
HEK 293A cells were transfected with plasmids containing Flag-FXR, HA-FoxO3a, 
HA or Flag. Total cell lysates were isolated, and Flag was pulled down by 
immunoprecipitation and subjected to immunoblot analysis for Flag and HA. Input 
total lysates from transfected HEK 293A were used as positive controls for FoxO3a 
and FXR (A). Cytosol and nuclear fractions also were obtained from transfected HEK 
293A cells, and immunoblot analysis was performed for Flag and FoxO3a (B). Age 
matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. FoxO3a in total liver lysates was pulled down by 




Ethanol-induced FoxO3a nuclear translocation was inhibited in FXR KO mouse 
livers.  
We next determined whether lack of FXR would affect the cellular localizations of 
FoxO3a in ethanol-treated mouse livers. Immunostaining analysis for endogenous 
FoxO3a revealed that acute ethanol treatment increased the number of cells with 
nuclear FoxO3a signals in WT but not in FXR KO mouse livers (Figure 5.11 A&B). To 
confirm the findings from the immunostaining analysis, cytosolic and nuclear fractions 
were prepared from WT and FXR KO mouse livers followed by immunoblotting analysis. 
We found that there was a decrease of cytosolic but increase of nuclear FoxO3a in WT 
mouse livers after ethanol treatment. However, acute ethanol treatment failed to 
increase nuclear FoxO3a levels in FXR KO mice (Figure 5.11C). These data suggest 
that acute ethanol-induced nuclear retention of FoxO3a is inhibited in FXR KO mouse 



















































Ethanol-induced FoxO3a nuclear translocation was diminished in FXR KO 
mouse livers. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Liver cyrosections were immunostained for FoxO3a, and 
representative images are shown in (A). Nuclei positive for FoxO3a were quantified 
from at least 3 images (B). Cytosolic and nuclear fractions were isolated from liver 
and subjected to immunoblot analysis for FoxO3a and FXR (C) Densitometry 




Acute ethanol treatment increased Akt-mediated FoxO3a phosphorylation and 
inhibited ethanol-induced FoxO3 binding in Map1lc3b promoter sites in FXR KO 
mouse livers  
Akt is the canonical regulator of FoxO3a, and sequesters FoxO3 into cytosol and 
decrease FoxO3a activity by promoting phosphorylation of FoxO3a (Tzivion, Dobson et 
al. 2011). We found that acute ethanol treatment slightly decreased the phosphorylation 
of Akt at serine 473 in WT mouse livers, which is consistent with our previous report (Ni, 
Du et al. 2013). Conversely, we found that acute ethanol treatment decreased 
phosphorylation of Akt, but dramatically increased the phosphorylation of Akt in FXR KO 
mouse livers by five-fold (Figure 5.12A). Glycogen synthase kinase beta (GSK3β) can 
be phosphorylated by Akt and thus serves as an indirect marker for Akt kinase activity. 
We found that the phosphorylation of GSK3β at serine 9 was reduced in ethanol-treated 
WT mouse livers. Furthermore, phosphorylation of GSK3β was enhanced by ethanol 
treatment in FXR KO mouse livers by around 2.5-fold (Figure 5.12A). These data 
suggest that acute ethanol treatment inhibits Akt activity in WT mouse livers but 
increases Akt activity in FXR KO mouse livers. As a result, we found that ethanol 
treatment attenuated the phosphorylation of FoxO3a at serine 253 in WT mouse livers 
but increased the phosphorylation of FoxO3a in FXR KO mouse livers (Figure 5.12B). 
Ethanol treatment increased total hepatic FoxO3a protein expression in WT mouse 
livers by two-fold but decreased the hepatic FoxO3a protein level in FXR KO mice. 
Since FoxO3a itself is a target gene of FoxO3a, these data thus may also imply that 
there is a decrease of FoxO3a transcriptional activity in FXR KO mouse livers after 
ethanol treatment compared to WT mice. We next performed ChIP analysis to 
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determine whether there would be any changes for FoxO3a binding on its target genes 
between WT and FXR KO mouse livers after ethanol treatment. It has previously been 
reported that FoxO3a binds to mouse Map1lc3b transcription promoter region in three 
different sites at approximately 1.5, 3.5 and 4.5 kilo base pairs upstream of the 
Map1lc3b transcription start site (Zhao, Brault et al. 2007). Indeed, ethanol increased 
FoxO3a binding to all three binding sites in WT mouse livers, but these bindings were 
significantly diminished in FXR KO mouse livers (Figure 5.12C). Collectively, these data 
suggest that ethanol treatment activates Akt and increased phosphorylation of FoxO3a 



























































Increased Akt activity resulted in inhibition of ethanol-induced FoxO3a binding 
in Map1lc3b promoter site in FXR KO mouse livers. 
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Total liver lysates were subjected to immunoblot analysis for 
serine 473 phosphorylated and total AKT, serine 9 phosphorylated and total GSK3β 
(A), and serine 253 phosphorylated and total FoxO3a (B). Densitometry analysis 
data are presented as a ratio of control (n = 3–4). Chromatin immunoprecipitation 
using FoxO3a antibody was performed to probe the three putative FoxO3a binding 
sites in Map1lc3b promoter site. DNA was isolated from chromatin pull-down and 
qPCR analysis was performed, and data was normalized to input chromatin. Relative 
binding abundance in comparison to untreated WT control was presented in (C). *: 
p<0.05  
Figure 5.12 Cont’d 
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Acute ethanol treatment had differential effect on sirtuin-1 protein expression and 
decreased FoxO3 acetylation in FXR KO mouse livers.  
 FoxO3a is a promiscuous binding partner, and Sirt1, a NAD-dependent 
deacetylase, and PGC-1α, a regulator of mitochondria biogenesis, are two reported co-
factors of FoxO3a (Brunet, Sweeney et al. 2004; Sandri, Lin et al. 2006; Olmos, Valle et 
al. 2009; Borniquel, Garcia-Quintans et al. 2010). We found that ethanol treatment did 
not increase PGC-1α protein levels in WT and FXR KO mouse livers.  Consistent with 
our previous findings, ethanol treatment decreased hepatic Sirt1 protein levels in WT 
mouse liver. However ethanol treatment increased Sirt1 protein levels in FXR KO 
mouse livers (Figure 5.13A). Furthermore, ethanol didn’t affect acetylation of FoxO3a in 
WT mouse livers, but decreased acetylation of FoxO3a in FXR KO mouse livers (Figure 
5.13B). Collectively, the data suggest that Sirt1 may mediate the decreased acetylation 
of FoxO3a in FXR KO mouse livers although future studies are needed to further 




























Acute ethanol treatment increased Sirt1 protein levels and decreased 
acetylation of FoxO3a in FXR KO mouse livers.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours. Total liver lysates were subjected to immunoblot analysis for 
PGC-1α and Sirt1 (A). Densitometry analysis data are presented as a ratio of control 
(n = 3–4). FoxO3a in total liver lysates was pulled down by immunopreciptation and 
subjected to immunoblot analysis for acetylated lysine and FoxO3a (B). 
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Acute ethanol treatment increased the number of mitochondrial spheroid in 
ethanol-treated FXR KO mouse livers  
 We previously reported that mitochondrial spheroids are induced and may serve 
as an alternative mitochondrial quality control pathway in response to stresses that 
induce mitochondrial damage as a result of impaired conventional mitophagy (Ding, 
Guo et al. 2012). In ethanol-treated FXR KO mouse livers, we found that some 
mitochondria underwent a dramatic structural remodeling that form a vesicular-like 
structure with enveloped contents. Some part of the mitochondria formed a four-
membrane structure with squeezed matrix (Figure 5.14A, arrows), which is consistent 
with the formation of mitochondrial spheroids that we previously reported (Ding, Guo et 
al. 2012). We did not detect any mitochondrial spheroids in either control or ethanol-
treated WT mouse livers but quantitative EM analysis showed increased number of 
mitochondrial spheroids in control FXR KO mouse livers, which was further increased 
after ethanol treatment (Figure 5.14B).  These results suggest that acute ethanol 
treatment may induce the formation of mitochondrial spheroids as an alternative 
mitochondrial quality control to compensate for the impaired autophagy in FXR KO 
mouse livers.  We previously demonstrated that Parkin negatively regulates the 
formation of mitochondrial spheroids by promoting the degradation of mitofusin 1 (Mfn1) 
and Mfn2, two important proteins that regulate mitochondrial fusion (Ding, Guo et al. 
2012; Yin and Ding 2013). Interestingly, we found that acute ethanol treatment caused 
almost 50% loss of hepatic Parkin. While the mechanisms of how ethanol decreased 
Parkin protein levels in the mouse livers were not clear, we have found that chronic plus 
binge alcohol treatment (Gao-binge) led to the Parkin mitochondrial translocation 
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(Williams JA et al, unpublished observations). Thus it is possible that the decreased 
Parkin in acute ethanol-treated mouse livers was due to the increased autophagic 
degradation of Parkin positive mitochondria (mitophagy). Interestingly, we also found 
increased degradation of Mfn1 and Mfn2 in ethanol-treated wild type mouse livers but 
the levels of Mfn1 and Mfn2 were less affected in FXR KO mouse livers (Figure 5.14C). 
The relatively higher levels of Mfn1 and Mfn2 in ethanol-treated FXO KO mouse livers 
than that of wild type mice may account for the increased mitochondrial spheroids 
formation in FXO KO mouse livers. We also found that acute ethanol treatment led to 
approximately 30% decrease on hepatic Lamp-1 and Lamp-2 proteins in both wild type 
and FXR KO mice (Figure 5.14C). Alcohol consumption has been implicated in 
impaired lysosomal functions but whether the decreased Lamp-1 and Lamp-2 would 
contribute to the impaired lysosomal functions need to be further studied. These results 
suggest that acute ethanol treatment may induce the formation of mitochondrial 
spheroids as an alternative mitochondrial quality control to compensate for the impaired 




















































Ethanol induced mitochondrial spheroid formation in FXR KO mouse livers.  
Age matched WT and FXR KO mice were treated with 4.5 g/kg ethanol or water by 
gavage for 16 hours.  Representative EM images of mitochondrial spheroids from 
FXR KO control (a) and ethanol-treated (b-e) liver sections were shown (A).  Arrows 
denote mitochondrial spheroids. Mitochondrial spheroid formation was quantified 
(>24 liver sections) (B). *: p<0.05. One-way ANOVA analysis. WT Ethanol vs FXR 
KO Ethanol. (C) Mice were treated as in (A), total liver lysates were subjected to 
western blot analysis followed by densitometry analysis. Densitometry analysis data 




FXR activation attenuated ethanol-induced steatosis.  
 We demonstrated that FXR KO mice have exacerbated ethanol-induced 
hepatotoxicity and steatosis.  Previous reports showed that FXR activation is protective 
against ethanol-induced hepatotoxicity and steatosis in mice that were fed with Lieber-
DeCarli ethanol diet (Livero, Stolf et al. 2014; Wu, Zhu et al. 2014). We treated WT mice 
with WAY-362450 (WAY), a potent FXR agonist, along with ethanol treatment. Serum 
ALT was increased in ethanol-treated mice, and was not further decreased with WAY 
co-treatment. Interestingly, we found that WAY also increased serum ALT levels, but it 
was not significant (Figure 5.15A). As expected, ethanol, but not WAY treatment 
increased hepatic triglycerides levels. Ethanol and WAY co-treatment attenuated 
ethanol-induced increase in hepatic triglycerides level, suggesting that activation of FXR 
by WAY may protect against ethanol-induced steatosis (Figure 5.15B). Furthermore, 
ethanol and WAY treatments did not affect liver weight/body weight ratio (Figure 
5.15C). These data suggest that FXR activation may protect against ethanol-induced 
steatosis, but not hepatotoxicity. Furthermore, WAY treatment increased total hepatic 
FoxO3a protein levels in untreated and ethanol-treated mice, which suggests that FXR 
activation may promote FoxO3a activation. However, we found that ethanol and WAY 
treatments and co-treatment did not change total hepatic Beclin-1, Atg5 and LC3-II 
protein levels. In line with our previous findings, ethanol treatment increased CYP2E1 
protein levels with and without WAY. Moreover, WAY treatment itself did not change 
CYP2E1 protein level (Figure 5.15D).  In the future, we need to perform autophagy flux 
assay to determine whether WAY has any effects on autophagy. Furthermore, the 
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effects of vehicle, the PEG400:Tween-20 mixture, on autophagy is not known and need 
to be examined.  
 The proposed cellular mechanism of how FXR regulates FoxO3a and 








































































   
 148 
 
FXR activation protected against ethanol-induced steatosis.  
WT mice were treated with 4.5 g/kg ethanol and/or 30 mg/kg WAY-362450 by 
gavage for 16 hours.  Serum alanine aminotransferase (ALT) (A) and hepatic 
triglycerides (TG) (B) were measured (n=4). Liver/body weight ratio was calculated 
(C) (n=4). Total liver lysates were subjected to immunoblot analysis for FoxO3a, 
Atg5, Beclin-1, LC3, and CYP2E1 (D). Densitometry analysis data are presented as 
a ratio of control (n = 3). *: p<0.05 
Figure 5.15 Cont’d














FXR deficiency results in impaired FoxO3-mediated autophagy induction, 
decreased mitophagy, and mitochondrial spheroid formation in response to 
acute ethanol exposure.  
Acute ethanol exposure induces FoxO3 activation and mitophagy as a protective 
mechanism. FXR deficiency promotes Akt activation and subsequent serine 253 
phosphorylation of FoxO3, resulting in decreased nuclear FoxO3 retention and 
abolished transcription of autophagy genes in response to ethanol; therefore, FXR 
KO mice displays defective hepatic autophagy, and results in impaired mitophagy in 
FXR KO mice. Impaired mitophagy results in accumulation of damaged mitochondria 
and oxidative stress; thus, autophagy-independent mitochondrial spheroid formation 
is initiated. Altogether, impaired FoxO3- mediated autophagy and mitophagy lead to 





In the present study, using an acute ethanol binge model, we showed that FXR 
KO mice had exacerbated steatosis and liver injury in comparison with WT mice. 
Mechanistically, following acute ethanol treatment, FXR KO mice had impaired hepatic 
autophagy due to the failure of activating FoxO3a-mediated up-regulation of autophagy 
related genes and likely reduced fusion of autophagosomes with lysosomes.   
It is well known that the nuclear receptor FXR is the master regulator of bile acid 
homeostasis. FXR deficiency caused an increased concentration of bile acid in the liver 
and serum due to activation of Cyp7A1 (Sinal, Tohkin et al. 2000; Kim, Morimura et al. 
2007). We previously reported that FXR KO mice had reduced hepatic autophagy likely 
due to impaired fusion of autophagosomes with lysosomes as a result of increased 
hepatic bile acid levels (Manley, Ni et al. 2014). In addition to removing cytosolic 
proteins and damaged/excess organelles, autophagy has been known to remove 
excess lipid droplets, a process named lipophagy (Singh, Kaushik et al. 2009). Impaired 
autophagy has been reported in many experimental non-alcoholic fatty liver disease and 
non-alcoholic steatohepatitis models, which was associated with endoplasmic reticulum 
(ER) stress and post-translational modifications of several autophagy proteins (Yang, Li 
et al. 2010; Ding, Manley et al. 2011). We also showed that fatty acids differentially 
regulated autophagy in which saturated fatty acids suppressed whereas unsaturated 
fatty acids induced autophagy in cultured hepatoma cells (Mei, Ni et al. 2011). In the 
context of alcoholic liver diseases, we also showed that pharmacological inhibition of 
autophagy exacerbated acute ethanol-induced steatosis (Ding, Li et al. 2010). 
Therefore, the impaired autophagy in FXR KO mice is likely one of the major 
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contributors for the exacerbated hepatic steatosis in acute ethanol-treated FXR KO 
mice. 
Interestingly, it has been reported that chronic ethanol exposure inhibited FXR 
activation, resulting in up-regulation of bile acid synthesis enzymes and down-regulation 
of bile acid transporter and in turn elevated hepatic bile acid pool (Xie, Zhong et al. 
2013; Wu, Zhu et al. 2014). Moreover, pharmacological activation of FXR using WAY-
362450 and 6α-ethyl-chenodeoxycholic acid (6ECDCA) attenuated chronic ethanol 
exposure-induced liver injury and steatosis (Livero, Stolf et al. 2014; Wu, Zhu et al. 
2014). While it is still controversial regarding the autophagy status in the mouse livers 
after chronic ethanol exposure, it has been suggested that chronic ethanol exposure 
may lead to impaired hepatic autophagy (Dolganiuc, Thomes et al. 2012). This notion is 
supported by the observations that chronic ethanol exposure leads to hepatomegaly 
(Baraona, Leo et al. 1975), accumulated ubiquitin positive protein aggregates 
(Zatloukal, French et al. 2007; Harada 2010) and decreased protein degradation 
(Donohue, Zetterman et al. 1989). In the future, it will be interesting to determine 
whether increased bile acid after chronic ethanol exposure would contribute to impaired 
hepatic autophagy and alcohol-induced liver injury. 
Emerging evidence supports that transcriptional regulation of the expression of 
autophagy related genes is critical in induction of autophagy in yeast (Williams, Primig 
et al. 2002; Bartholomew, Suzuki et al. 2012), Caenorhabditis elegans (Yang and Zhang 
2014) and mammals (Pietrocola, Izzo et al. 2013; Fullgrabe, Klionsky et al. 2014). 
Among the several known transcriptional factors that regulate autophagy, the FoxO 
family members play critical roles in regulating expression of autophagy related genes 
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in skeletal muscles (Mammucari, Milan et al. 2007; Zhao, Brault et al. 2007), 
cardiomyocytes (Sengupta, Molkentin et al. 2011) and liver (Xiong, Tao et al. 2012). In 
addition, cytosolic FoxO proteins also showed to regulate autophagy independent of 
their transcriptional activity (van der Vos, Eliasson et al. 2012). We also recently 
demonstrated that FoxO3a is critical for ethanol-induced hepatic autophagy, and play a 
protective role against ethanol-induced liver injury (Ni, Du et al. 2013). In agreement 
with our previous findings, we found that ethanol induced FoxO3a-mediated expression 
of autophagy related genes in WT mouse livers. The activation of FoxO3a is mainly 
regulated by its post-translational modifications including phosphorylation, acetylation, 
ubiquitination and methylation. It has been well-documented that FoxOs are 
phosphorylated by the serine/threonine protein kinase Akt and become sequestered in 
the cytoplasm, where they are unable to regulate gene expression (Tzivion, Dobson et 
al. 2011).  In WT mice, we found that acute ethanol treatment decreased the level of 
phosphorylated Akt and FoxO3a and in turn increased nuclear retention of FoxO3a.  In 
contrast, acute ethanol treatment increased Akt activity resulting in the increased 
phosphorylation of FoxO3a and decreased nuclear retention FoxO3a in FXR KO mouse 
livers.  Currently it is not clear how Akt was activated in FXR KO mouse livers. 
However, FXR KO mice develop spontaneous hepatocellular carcinoma (Yang, Huang 
et al. 2007), and increased AKT activity can promote tumorigenesis (Bellacosa, Kumar 
et al. 2005). In addition to post-translational modifications, FoxO family members 
including FoxO3a bind to a variety of nuclear hormone receptors to regulate either its 
own or nuclear hormone receptors’ DNA binding affinity and transcriptional activity (van 
der Vos and Coffer 2008). FoxO3a contains LxxLL motif in the C-terminal of forkhead 
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DNA binding region, which may enable FoxO3a to interact with nuclear hormone 
receptors (van der Vos and Coffer 2008; Wang, Marshall et al. 2012). Thus it is possible 
that the decreased FoxO3a-mediated expression of autophagy related genes is due to 
the lack of a direct interaction between FoxO3a and FXR. However, the failure to detect 
the direct interaction between FXR and FoxO3a both in vitro and in vivo excludes this 
possibility. In addition, we also found that acute ethanol treatment increased the binding 
of FoxO3a to the promoter regions of Map1lc3b in WT but not in FXR KO mouse livers 
by the ChIP assay. While the increased nuclear retention of FoxO3a in ethanol-treated 
WT mouse livers could contribute to these observations, it is also likely that other 
FoxO3a co-factors/suppressors may influence the binding of FoxO3a to the promoter 
regions of Maplc3b. It is known that FoxO3a also interacts with other co-factors such as 
PGC1-α (Sandri, Lin et al. 2006; Olmos, Valle et al. 2009; Borniquel, Garcia-Quintans et 
al. 2010) and p300/CBP (van der Heide and Smidt 2005). Future studies will be needed 
to determine the changes of the interactions of FoxO3a with PGC1-α or p300/CBP after 
ethanol treatment in WT and FXR KO mice.  
In addition to the defect of FoxO3a-mediated transcriptional regulation of 
autophagy in FXR KO mouse livers, increased bile acid levels may also contribute to 
the impaired autophagy in FXR KO mouse livers. As we previously demonstrated that 
bile acids themselves did not have any effects on the expression of autophagy related 
genes regardless of the conjugated or unconjugated bile acids (Manley, Ni et al. 2014). 
However, bile acids impaired the fusion of autophagosomes with lysosomes through the 
alteration of intracellular Rab7, a key protein that regulates the fusion of 
autophagosomes with lysosomes (Manley, Ni et al. 2014). The increased number of 
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autophagosomes in ethanol-treated FXR KO mouse livers may reflect the impaired 
fusion of autophagosomes with lysosomes. Thus it is likely that the combination of 
impaired FoxO3a-mediated expression of autophagy related genes and bile acid-
mediated defect on the fusion of autophagosomes with lysosomes contribute to the 
exacerbated steatosis and liver injury in ethanol-treated FXR KO mice. 
 It is known that alcohol consumption can lead to increased oxidative stress and 
mitochondrial damage (Hoek, Cahill et al. 2002; Ding, Manley et al. 2011). Metabolism 
of alcohol may play a critical role in alcohol-induced oxidative stress and mitochondrial 
damage.  Alcohol is mainly metabolized in the liver through cytosolic alcohol 
dehydrogenase (ADH) to acetaldehyde, a highly reactive molecule that is further 
metabolized through mitochondrial acetaldehyde dehydrogenase (ALDH) to acetate. 
Consequently, alcohol metabolism increases hepatic NADH/NAD+ ratio and oxidative 
stress. Moreover, alcohol can also induce hepatic Cyp2E1 expression to oxidize 
alcohol, which also leads to increased oxidative stress and mitochondrial damage (Wu 
and Cederbaum 1996). Previous works including ours have shown that the metabolism 
of alcohol either via ADH or Cyp2E1 is important for alcohol-induced changes on 
hepatic autophagy (Ding, Li et al. 2010; Wu, Wang et al. 2012; Thomes, Ehlers et al. 
2013). Interestingly, we found that the levels of hepatic Cyp2E1 were much higher 
induced by acute ethanol treatment in FXR KO mice than wild type mice. It is likely that 
the higher levels of Cyp2E1 in FXR KO mouse livers may also contribute to the 
increased liver injury by acute ethanol treatment. Future studies will be needed to 
further determine the levels of hepatic oxidative stress after ethanol treatment in FXR 
KO mice.  
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We also previously demonstrated that at least one purpose of acute ethanol-
induced autophagy is to remove damaged mitochondrial through mitophagy (Ding, Li et 
al. 2010; Ding, Li et al. 2011). However, increased evidence suggests that cells may 
use alternative pathways or activate other forms of autophagy (i.e. microautophagy or 
chaperone-mediated autophagy) to regulate cellular organelle homeostasis (Cuervo and 
Wong 2014). We recently reported that several mitochondrial damage stressors induce 
the formation of mitochondrial spheroids likely as an alternative pathway to regulate 
mitochondrial homeostasis in cultured cells or mouse livers in both WT and autophagy-
deficient cells (Ding, Guo et al. 2012). Interestingly, we also found that acute ethanol 
treatment increased the number of mitochondrial spheroids in FXR KO but not WT 
mouse livers. Moreover, mitochondrial spheroid structures were also found in the 
control FXR KO mouse livers. It is likely that increased bile acid levels might induce 
mitochondrial damage in control FXR KO mouse livers, which was further exacerbated 
after ethanol treatment. Damaged mitochondria can normally be removed via mitophagy 
but this process was impaired in FXR KO mouse livers. The increased mitochondrial 
spheroid in ethanol-treated FXR KO mouse livers thus may also serve as an alternative 
pathway to regulate mitochondrial homeostasis in FXR KO mouse livers.  
 In conclusion, we demonstrated that FXR is a protective factor against ethanol-
induced hepatotoxicity and steatosis. Furthermore, we also showed that FXR is 
associated with ethanol-induced FoxO3a activation and FoxO3a-mediated autophagy. 
















CHAPTER 6:  













6.1 General Conclusions 
The present dissertation presents a novel insight in how bile acids mediate hepatic 
autophagy, and play a role in liver pathogenesis, in particular, alcohol-induced liver 
injury. We showed that bile acids induce hepatocyte apoptosis by initiating cleavage of 
caspase-3. We demonstrated that bile acids impair autophagy in hepatocytes via 
inhibiting the fusion of autophagosomes with lysosomes by altering intracellular Rab7 
protein. Bile acids did not affect lysosomal functions or the ubiquitin-proteasome 
system. Furthermore, whole body FXR deficient mice displayed defective hepatic 
autophagy mediated by elevated hepatic bile acids, which could play a role in liver 
tumorigenesis found in FXR deficient mice. Using an acute alcohol mouse model, we 
further found that FXR deficiency exacerbated ethanol-induced hepatotoxicity and 
steatosis in mice. Moreover, FXR is required for ethanol-induced FoxO3a activation and 
FoxO3a-induced autophagy. Ethanol treatment increases Akt activity and subsequent 
phosphorylation and sequestration of FoxO3a in the cytosol, resulting in FoxO3a 
inactivation in FXR deficient mice. Impaired hepatic autophagy in FXR deficient mice 
may increase ethanol-induced mitochondria stress due to defective mitophagy, resulting 
in mitochondrial spheroid formation as a compensatory mechanism for mitochondria 
quality control. Altogether, we demonstrated how bile acids and FXR play a major role 
in liver physiology and pathogenesis by modulating autophagy and stress response, 
especially as it relates to ethanol. This dissertation shows how little we know about bile 




6.2 Future directions 
Clarifying the Effects of Bile Acids on the Autophagosomal-Lysosomal Fusion 
Machinery 
 This dissertation demonstrated that bile acids inhibit autophagosomal-lysosomal 
fusion by altering Rab7 protein expression in hepatocytes. However, the molecular 
mechanism by which bile acids alter Rab7, and possibly other fusion machinery 
proteins, is not clear. Rab7 is a small GTPase protein that has been used as a late 
endosome marker (Bottger, Nagelkerken et al. 1996), and is demonstrated to have 
functions in late endosomal transport (Vitelli, Santillo et al. 1997; Press, Feng et al. 
1998) and lysosomal biogenesis (Bucci, Thomsen et al. 2000). Furthermore, Rab7 is 
also required for completion of autophagosomal-lysosomal fusion (Jager, Bucci et al. 
2004; Ganley, Wong et al. 2011). Thapsigargin is a sesquiterpene lactone that inhibits 
calcium-ATPase in the endoplasmic reticulum, resulting in a release of calcium from 
stores and subsequent increase in cytosolic calcium concentration (Thastrup, Cullen et 
al. 1990). Thapsigargin blocks autophagosomal-lysosomal fusion by blocking the 
recruitment of Rab7 to autophagosomes (Ganley, Wong et al. 2011). However, the 
mechanism of the blockage is not completely understood. On the other hand, bile acids 
have been shown to induce calcium release from the endoplasmic reticulum and 
intracellular calcium stores (Gerasimenko, Flowerdew et al. 2006). Interestingly, CDCA 
and TCA (at high doses) also increased intracellular calcium concentration in rat 
hepatocytes (Thibault and Ballet 1993). Moreover, exogenously introduced calcium 
using calcium phosphate precipitates induces autophagosome accumulation by 
blocking autophagosomal-lysosomal fusion at 24 hours (Sarkar, Korolchuk et al. 2009). 
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We also showed that bile acids inhibit autophagosomal-lysosomal fusion by blocking the 
recruitment of Rab7 to the autophagosomes. Therefore, it is possible that bile acids may 
alter calcium signaling and thus affect Rab7 activity and cellular localization. Future 
experiments are needed to further explore these possibilities.  
 Rab7 is one of the essential proteins for autophagosomal-lysosomal fusion. 
However, the autophagosomal-lysosomal fusion machinery is not completely elucidated 
yet. Multiple proteins and complexes have been shown to be involved in the fusion 
machinery, including the SNARE complexes and HOPS complexes. Syntaxin 17, a 
SNARE protein, has been identified as another required component for the fusion of 
autophagosomes with lysosomes by interacting with the following specific HOPS 
complex proteins: vacuolar sorting protein 33A (VPS33A), VPS16, and VPS39 (Itakura, 
Kishi-Itakura et al. 2012; Jiang, Nishimura et al. 2014). Currently, the effect of bile acids 
on fusion machinery other than Rab7 is unknown. Therefore, it will be interesting to see 
whether bile acids block interaction of the SNARE proteins with the HOPS complex 
proteins.   
Role of autophagy and p62 in liver tumorigenesis 
Autophagy is a bona fide tumor suppressor, and deletion or partial knockdown of 
autophagy genes, including Atg5 (Takamura, Komatsu et al. 2011), Atg7 (Inami, Waguri 
et al. 2011; Takamura, Komatsu et al. 2011), and Beclin-1 (Qu, Yu et al. 2003), results 
in spontaneous liver tumorigenesis. Deletion of autophagy results in p62 positive protein 
aggregates accumulation, persistent Nrf2 activation, disruption of mitochondria 
homeostasis, and elevated oxidative stress, which all together drive tumorigenesis. The 
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p62 protein is an autophagy receptor protein responsible for recruiting ubiquitinated 
protein aggregates and organelles to the autophagosomes for degradation, which 
results in degradation of p62 as well (Manley, Williams et al. 2013). Over expression of 
p62 enhances tumorigenesis in autophagy-deficient cells, whereas tumor progression is 
significantly stunted in Atg7/p62 double KO mice (Takamura, Komatsu et al. 2011). 
Moreover, p62 may drive tumorigenesis through persistent Nrf2 activation (Inami, 
Waguri et al. 2011). The p62 protein binds to Keap1 at the same site as Nrf2, and 
excessive p62 dissociates Nrf2 from Keap1, resulting in up regulation of Nrf2 activation 
(Jain, Lamark et al. 2010; Lau, Wang et al. 2010; Manley, Williams et al. 2013). Our 
research group has demonstrated that Atg5/Nrf2 double KO mice completely abolished 
liver tumorigenesis that was found in hepatocyte-specific Atg5 KO mice (Ni, Woolbright 
et al. 2014). Moreover, p62 also has been shown to inhibit phosphatase and tensin 
homolog (PTEN), a tumor suppressor in mammary tumors. The p62-mediated inhibition 
of PTEN results in activated Akt, beta-catenin stabilization and nuclear translocation, 
and subsequent cyclin D1 up regulation (Cai-McRae, Zhong et al. 2014).  Altogether, 
p62 appears to play a pivotal role in tumorigenesis.  
FXR is also a tumor suppressor, and FXR deficiency results in spontaneous 
hepatic tumorigenesis in mice (Kim, Ahn et al. 2007; Yang, Huang et al. 2007).  The 
mechanism of tumorigenesis in FXR KO mice is not fully understood. Bile acid 
sequestrant, cholestyramine, has been shown to lower the bile acids pool and reduce 
the number of malignant tumors (Yang, Huang et al. 2007).  Moreover, liver specific 
FXR-deficient mice display normal bile acids level and an absence of liver 
tumorigenesis (Kong, Li et al. 2012), and our work showed that hepatic autophagy is not 
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impaired in liver specific FXR KO mice. The results suggest that bile acids may drive 
tumorigenesis (Borude, Edwards et al. 2012; Kong, Wang et al. 2012). Cholic acid 
feeding also promotes N,N-diethylnitrosamine-induced tumorigenesis (Shiota, Oyama et 
al. 1999; Yang, Huang et al. 2007), and in the clinical cases, cholestasis results in liver 
tumorigenesis (Jansen 2007). Our research showed that bile acids impair autophagy 
and initiate p62 accumulation in vitro. Moreover, we found that p62 is accumulated in 
FXR KO mouse livers, suggesting that p62 may participate in bile-acid-driven liver 
tumorigenesis by inhibiting hepatic autophagy (Manley, Ni et al. 2014).  
We demonstrated that ethanol treatment exacerbates p62 accumulation in FXR 
deficient mouse livers due to impaired autophagy. A small fraction of alcoholic liver 
disease patients subsequently progresses to hepatocellular carcinoma (Gao and 
Bataller 2011), and FXR activation may play a role in the protection against ALD 
progression. The relationship between FXR, alcohol, and p62 in alcohol-induced 
hepatocellular carcinoma progression currently is not known, and appears to be a 
promising field of study for future therapies. It also will be interesting to examine 
whether ethanol-induced p62 accumulation in FXR KO mice induces Nrf2 activation, 
reduces PTEN protein expression and activates Akt- GSK3β-beta-catenin signaling 
axis, resulting in possible subsequent tumor growth.  
Modulating Autophagy and FXR in Cholestasis  
The dissertation showed that FXR indirectly regulates autophagy through bile 
acid homeostasis, and whole body FXR deficiency results in impaired autophagy 
through the accumulation of hepatic bile acids. Cholestasic patients show markedly 
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reduced FXR activation (Chen, Ananthanarayanan et al. 2004; Cai, Gautam et al. 2009; 
Jonker, Liddle et al. 2012). Moreover, we demonstrated that cholestasic mouse models 
display p62 accumulation, possibly due to bile acid-mediated impaired hepatic 
autophagy. Mallory-Denk bodies (MDB) are p62-positive intracellular protein 
aggregates, and are the hallmark of liver pathogenesis, including alcoholic 
steatohepatitis (Manley, Williams et al. 2013). Furthermore, cholic acid feeding and 
common bile duct ligation result in the formation of MDBs in drug-primed mice, 
suggesting that bile acids may drive the formation of MDBs (Fickert, Trauner et al. 
2002). The formation of MDBs is also observed in the liver tissues from cholestatic 
patients afflicted with either primary biliary cirrhosis (PBC) or primary sclerosing 
cholangitis (PSC) (Gerber, Orr et al. 1973; Fickert, Trauner et al. 2002; Strnad, 
Zatloukal et al. 2008). Interestingly, the liver tissues from PBC patients display LC3-II 
and p62 accumulation (Sasaki, Miyakoshi et al. 2012; Sasaki, Miyakoshi et al. 2012). It 
will be interesting to determine whether induction of autophagy and FXR using a 
pharmacological approach may alleviate cholestasic liver disease by the elimination of 
p62-positive protein aggregates and the restoration of FXR-mediated bile acid 
homeostasis.  
The Role of FXR in Ethanol-Induced Hepatotoxicity and Steatosis  
The dissertation demonstrated that ethanol-induced liver injury and steatosis are 
exacerbated in FXR KO mice due to impaired autophagy and the lack of FoxO3a 
activation. Currently, the protective mechanism of FXR activation is not clearly 
understood.  
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 Chronic ethanol treatment has been reported to inhibit FXR activation and disrupt 
bile acid homeostasis by decreasing transcription of the FXR target gene, Bsep, and by 
abolishing SHP-mediated inhibition of transcription of the bile acid synthesis genes, 
CYP7A1 and CYP8B1 (Xie, Zhong et al. 2013; Wu, Zhu et al. 2014). Moreover, chronic 
ethanol treatment has been demonstrated to decrease Sirt1, a deacetylase, and 
increase p300, an acetyltransferase, resulting in acetylation of and subsequent 
inactivation of FXR (Ni, Du et al. 2013; Wu, Zhu et al. 2014). In accordance with 
previous reports, we demonstrated that acute ethanol treatment attenuates Sirt1 protein 
levels. However, the effects of acute ethanol treatment on FXR activation, bile acid 
metabolism, and hepatic transporters are not known.  
 Other possible protective mechanisms by FXR activation are reduced CYP2E1 
activity and decreased generation of reactive oxygen species.  Administration of the 
FXR agonist, WAY-362450, has been shown to repress chronic ethanol-mediated 
CYP2E1 induction resulting in decreased oxidative stress (Wu, Zhu et al. 2014). 
Another FXR agonist, 6-ECDCA, has been demonstrated to attenuate chronic ethanol-
induced ROS generation (Livero, Stolf et al. 2014). However, this dissertation showed 
that WAY-362450 did not attenuate acute ethanol-induced CYP2E1 protein levels. 
Increased CYP2E1 activity has been suggested to be the culprit of ethanol-induced 
ROS generation in addition to ADH (Caro and Cederbaum 2004). Ethanol has been 
shown to increase CYP2E1 protein levels by protein stabilization (Lu and Cederbaum 
2008). Moreover, impaired autophagy has been reported to promote CYP2E1-
dependent toxicity in vivo and in vitro (Wu and Cederbaum 2013). Currently, it is not 
clear how FXR regulates CYP2E1 protein expression in response to ethanol treatment.  
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 In addition to being the master regulator of bile acid homeostasis, FXR also 
regulates lipid metabolism by several mechanisms. FXR activation indirectly represses 
expression of sterol regulatory element-binding transcription factor 1 (SREBP1) through 
SHP, resulting in decreased transcription of lipogenic target genes (Zhang, Castellani et 
al. 2004). Paradoxically, FXR directly activates the transcription of fatty acid synthase 
(FAS), a key lipogenic gene, suggesting FXR may bypass SHP-mediated inhibition of 
lipogenesis (Matsukuma, Bennett et al. 2006). Ethanol has been reported to induce 
SREBP1-mediated lipogenesis (You, Fischer et al. 2002; Gao and Bataller 2011). 
Activation of FXR by 6-EDCA has been showed to repress chronic ethanol-induced 
transcription of the lipogenesis genes, SREBP1 and FAS (Livero, Stolf et al. 2014). 
Autophagy is important for hepatic lipid droplet removal and impaired autophagy 
exacerbates ethanol-induced steatosis (Ding, Li et al. 2010; Czaja 2011). Currently, the 
role of FXR in regulation of ethanol-induced steatosis is largely unknown, and the 
preliminary studies suggested that FXR activation might protect against ethanol-induced 
steatosis possibly through the inhibition of SREBP1-mediated lipogenesis and 
maintenance of autophagy.  
Regulation of FoxO3a Activation in Ethanol-Induced Hepatotoxicity 
 This dissertation demonstrated that FXR deficiency indirectly inhibits ethanol-
induced FoxO3a activation by up-regulating the Akt signaling pathway. Akt is a well-
established canonical regulator of FoxO3a activation. However, emerging evidence 
demonstrates that multiple biochemical pathways are involved in the regulation of 
FoxO3a activation (Calnan and Brunet 2008; Tzivion, Dobson et al. 2011; Tikhanovich, 
Cox et al. 2013).  Currently, the effects of acetylation on FoxO3a is not completely 
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understood, but it has been suggested that acetylated FoxO3a has decreased DNA-
binding affinity (Calnan and Brunet 2008). Moreover, our group has reported that 
ethanol induces acetylation of FoxO3a. However, Sirt1 activation by resveratrol 
enhances ethanol-induced FoxO3a activation and transcription of autophagy related 
genes (Ni, Du et al. 2013). Surprisingly, we found that ethanol decreases FoxO3a 
acetylation and also decreases FoxO3a binding to the DNA in FXR KO mouse livers, 
suggesting that other post-translational modifications may be involved. We also found 
that ethanol increases Akt-mediated serine 253 phosphorylation of FoxO3a in FXR KO 
mouse livers, resulting in cytoplasmic sequestration of FoxO3a. These data suggest 
that cytoplasmic sequestration of FoxO3a is more important than acetylation in ethanol-
induced liver injury in FXR KO mice. Moreover, total hepatic FoxO3a level was 
decreased in ethanol-treated FXR KO mice, which suggest that FoxO3a could be 
decreased due to either decreased FoxO3a mRNA level or increased degradation of 
FoxO3a. However, the mechanism of FoxO3a degradation was not elucidated. 
Interestingly, deacetylation of FoxO3a by Sirt1 may result in Skp2-mediated 
ubiquitination of FoxO3a and subsequent FoxO3a degradation (Wang, Chan et al. 
2012). This mechanism may explain why FXR KO mice displayed both decreased 
acetylation of FoxO3 and hepatic FoxO3a levels, but further investigation is required. 
Moreover, the mechanism of how FoxO3a binds to DNA in response to ethanol needs 




6.3 Why Do We Care about the Alcohol Abuse, a Self-Inflicted Malady?  
 Alcohol is ubiquitous in the United States. According to the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA), almost 9 out of 10 adults reported that they had 
drunk alcohol in their lifetime (SAMHSA). Moreover, about 1 out of 4 adults reported 
that they had engaged in binge drinking (SAMHSA).  Centers for Disease Control and 
Prevention also reported that alcohol is directly responsible for 88,000 deaths annually 
in the United States (CDC). Interestingly, alcohol misuses cost $223.5 billion per year in 
the United States alone, and around three-quarters of the cost is due to binge drinking 
(CDC).  In 2009, alcohol liver disease was the primary reason for 1 in 3 liver 
transplantions in the United States (Singal, Guturu et al. 2013). Moreover, alcoholism is 
a self-inflicted disease that not only affects individuals, but also their families, in which 
10% of children live with parents with alcohol problems in the United States (SAMHSA 
2012). Despite the profound influence of alcoholism on the economy and family 
structure, very little progress had been made in ALD research and therapeutics. No 
novel treatment has been proposed for ALD since the 1970s, in which corticosteroids 
were used to treat alcoholic steatohepatitis. The lack of progression can be attributed to 
the limitations of animal models, and the difficulty in recruiting patients with active 
addiction for clinical trials (Gao and Bataller 2011). Rodent models have yielded some 
novel insights. However, the manifestations of alcohol-induced liver injury in rodent 
models are very mild and never progress past simple steatosis and mild inflammation 
(Bertola, Mathews et al. 2013). Our long-term goal is to identify novel therapeutic 
targets despite the limitations, so we can improve the quality of life for alcoholics, and 
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